<table>
<thead>
<tr>
<th>Model List of Essential Medicines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BCG vaccine</strong></td>
</tr>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Recommendations for all immunization programmes</td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Need for immunization against tuberculosis</td>
</tr>
</tbody>
</table>

| **Japanese encephalitis vaccine** |
| **Section**                       |
| Recommendations for certain regions |
| All vaccines should comply with the WHO requirements for biological substances. |
| **Indications**                   |
| Need for immunization against certain single viral diseases |

| **Abacavir**                      |
| **Section**                       |
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors |
| Oral > Solid: 300 mg tablet (as sulfate) |
| **Indications**                   |
| Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

| **Abacavir + lamivudine**         |
| **Section**                       |
| Fixed-dose combinations of antiretrovirals |
| Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored) |
| **Indications**                   |
| Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

| **Abacavir + lamivudine + lopinavir + ritonavir** |
| **Section**                       |
| Fixed-dose combinations of antiretrovirals |
| Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules |
| **Indications**                   |
| Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

| **Abiraterone**                   |
| **Section**                       |
| Hormones and antihormones         |
| Oral > Solid: 250 mg; 500 mg       |
| **Indications**                   |
| Malignant neoplasms of prostate   |
### Acetazolamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmological preparations &gt; Miotics and antiglaucoma medicines</td>
<td>Primary open-angle glaucoma</td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Acetic acid

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ear, nose and throat medicines [c]</td>
<td>Infectious diseases of external ear</td>
</tr>
<tr>
<td>Local &gt; Otological &gt; drops: 2% in alcohol</td>
<td></td>
</tr>
</tbody>
</table>

### Acetylcysteine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Specific</td>
<td>Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 200 mg per mL in 10 mL ampoule</td>
<td>Acute or subacute hepatic failure</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 10%; 20%</td>
<td></td>
</tr>
</tbody>
</table>

### Acetylsalicylic acid

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimigraine medicines &gt; For treatment of acute attack</td>
<td>Migraine</td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 to 500 mg</td>
<td></td>
</tr>
<tr>
<td>Anti-platelet medicines</td>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg</td>
<td>Cerebral ischaemic stroke</td>
</tr>
<tr>
<td>Medicines for juvenile joint diseases</td>
<td>Mucocutaneous lymph node syndrome</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 to 500 mg</td>
<td>Acute rheumatic fever without mention of heart involvement</td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Suppository: 50 to 150 mg</td>
<td>Juvenile idiopathic arthritis</td>
</tr>
<tr>
<td>Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)</td>
<td>Pain</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 to 500 mg</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Suppository: 50 to 150 mg</td>
<td></td>
</tr>
</tbody>
</table>
# Aciclovir

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiviral medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 250 mg in vial powder for injection (as sodium salt)</td>
<td>Zoster</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 200 mg per 5 mL</td>
<td>Varicella</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg tablet</td>
<td>Herpes simplex infections</td>
</tr>
<tr>
<td>Ophthalmological preparations &gt; Anti-infective agents</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Ointment: 3% w/w</td>
<td>Herpes simplex keratitis</td>
</tr>
</tbody>
</table>

# Aclidinium

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong></td>
<td>Therapeutic equivalent to tiotropium bromide for</td>
</tr>
<tr>
<td></td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
</tbody>
</table>

# Activated charcoal

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antidotes and other substances used in poisonings &gt; Non-specific</strong></td>
<td>Unspecified injury, poisoning or certain other consequences of external causes</td>
</tr>
<tr>
<td>Oral &gt; Other: powder</td>
<td></td>
</tr>
</tbody>
</table>

# Adalimumab

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunomodulators for non-malignant disease</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL</td>
<td>Axial spondyloarthritis</td>
</tr>
<tr>
<td></td>
<td>Crohn disease site</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
</tr>
</tbody>
</table>

| Medicines for juvenile joint diseases | |
| Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL | Juvenile idiopathic arthritis |

# Afatinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted therapies</strong></td>
<td>Therapeutic equivalent to erlotinib for</td>
</tr>
<tr>
<td></td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Antifilarials</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg tablet (chewable)</td>
<td>Filariasis</td>
</tr>
<tr>
<td><strong>Intestinal anthelmintics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg tablet (chewable)</td>
<td>Echinococcosis Enterobiosis Ascariasis Trichuriasis Hookworm diseases Cysticercosis</td>
</tr>
<tr>
<td><strong>Cysticidal medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg tablet (chewable)</td>
<td>Other specified echinococcosis Cysticercosis of central nervous system</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alcohol based hand rub</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Disinfectants</strong></td>
<td>Denatured alcohol</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alcuronium</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Muscle relaxants (peripherally-acting) and cholinesterase inhibitors</strong></td>
<td>Muscle relaxants</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-trans retinoic acid</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Targeted therapies</strong></td>
<td>Acute myeloid leukaemia with recurrent genetic abnormalities</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg capsule</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allopurinol</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Medicines used to treat gout</strong></td>
<td>Gout</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Supportive medicines</strong></td>
<td>Tumour lysis syndrome</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 300 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Thrombolytic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td></td>
</tr>
<tr>
<td>Cerebral ischaemic stroke</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Amidotrizoate</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Amidotrizoate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Amikacin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Therapeutic equivalent to gentamicin for Other specified conjunctivitis</td>
</tr>
<tr>
<td>Therapeutic equivalent to gentamicin for Infectious blepharitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Access group antibiotics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First choice</strong></td>
</tr>
<tr>
<td>Neutropenia (high-risk)</td>
</tr>
<tr>
<td>co-prescribed with cefotaxime</td>
</tr>
<tr>
<td>Inflammatory and other diseases of prostate (severe)</td>
</tr>
<tr>
<td>co-prescribed with cefotaxime</td>
</tr>
<tr>
<td>Acute pyelonephritis (severe)</td>
</tr>
<tr>
<td>co-prescribed with ceftriaxone</td>
</tr>
<tr>
<td>Inflammatory and other diseases of prostate (severe)</td>
</tr>
<tr>
<td>co-prescribed with ceftriaxone</td>
</tr>
<tr>
<td>Acute pyelonephritis (severe)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Second choice</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis without septic shock</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Antituberculosis medicines</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
</tbody>
</table>
## Amiloride

### Section

**Diuretics**

*Oral > Solid: 5 mg (hydrochloride)*

**Indications**

- Oedema
- Ascites

## Amiodarone

### Section

**Antiarrhythmic medicines**

*Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)*

*Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)*

**Indications**

- Cardiac arrhythmia

## Amitriptyline

### Section

**Medicines for other common symptoms in palliative care**

*Oral > Solid: 25 mg; 10 mg; 75 mg*

**Medicines for depressive disorders**

*Oral > Solid: 25 mg; 75 mg*

**Indications**

- Palliative care
- Depressive disorders

## Amlodipine

### Section

**Antihypertensive medicines**

*Oral > Solid: 5 mg (as maleate, mesylate or besylate)*

**Indications**

- Essential hypertension

## Amodiaquine

### Section

**Antimalarial medicines > For curative treatment**

*Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)*

**Indications**

- Malaria due to Plasmodium falciparum
- Malaria due to Plasmodium vivax

## Amodiaquine + sulfadoxine + pyrimethamine

### Section

**Antimalarial medicines > For chemoprevention**

*Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package*

**Indications**

- Malaria
## Access group antibiotics

<table>
<thead>
<tr>
<th>Indications</th>
<th>Access group antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First choice</strong></td>
<td><strong>Access group antibiotics</strong></td>
</tr>
<tr>
<td>Acute malnutrition in infants, children or adolescents (uncomplicated) [children]</td>
<td>Oral &gt; Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid</td>
</tr>
<tr>
<td>Acute malnutrition in infants, children or adolescents (complicated) [children]</td>
<td>Oral &gt; Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)</td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection</td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td>Oral &gt; Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid</td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td>Oral &gt; Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet</td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td>Oral &gt; Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)</td>
</tr>
<tr>
<td>Acute sinusitis</td>
<td><strong>Second choice</strong></td>
</tr>
<tr>
<td>Bacterial meningitis</td>
<td><strong>Other indications</strong></td>
</tr>
<tr>
<td>Sepsis without septic shock</td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Periapical abscess without sinus</td>
<td>Amoxicillin</td>
</tr>
<tr>
<td>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</td>
<td><strong>Amoxicillin</strong></td>
</tr>
</tbody>
</table>
| Bacterial pneumonia (Community-acquired pneumonia - severe) [children] | "Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid"
| **Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate) | **Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet** |
| **Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)"** | **Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection** |
| **Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid** | **Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet** |
| **Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)"** | **Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid** |
| **Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet** | **Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)"** |
| **Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)"** | **Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet"** |
# Amoxicillin + clavulanic acid

## Access group antibiotics

**Parenteral** > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

**Oral** > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

**Oral** > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid

**Oral** > Solid: 500 mg + 125 mg tablet

**Oral** > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid

**Oral** > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

## Indications

### First choice

- Neutropenia (low-risk)
- Other specified pneumonia (Hospital-acquired pneumonia)
- Bacterial cellulitis, erysipelas or lymphangitis
- Acute sinusitis
- Peritoneal abscess (mild-moderate)
- Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
- Peritonitis (mild-moderate)
- Infectious cystitis
- Chronic obstructive pulmonary disease with acute exacerbation

### Second choice

- Osteomyelitis or osteitis
- Acute otitis media
- Bacterial infection of joint
- Other specified prophylactic measures
- Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

**co-prescribed with clarithromycin**

- Bacterial pneumonia (Community-acquired pneumonia - severe)

### Other indications

- Bacterial infection of unspecified site
- Multi-drug resistant Mycobacterium tuberculosis

## Antituberculosis medicines

**Oral** > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid

**Oral** > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
### Amphotericin B

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungal medicines</strong></td>
<td><strong>Blastomycosis</strong>&lt;br&gt;<strong>Aspergillosis</strong>&lt;br&gt;<strong>Cryptococcosis</strong>&lt;br&gt;<strong>Candidosis</strong>&lt;br&gt;<strong>Coccidioidomycosis</strong>&lt;br&gt;<strong>Histoplasmosis</strong>&lt;br&gt;<strong>Sporotrichosis</strong></td>
</tr>
<tr>
<td><strong>Antileishmaniasis medicines</strong></td>
<td><strong>Visceral leishmaniasis</strong></td>
</tr>
</tbody>
</table>

### Ampicillin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access group antibiotics</strong></td>
<td><strong>First choice</strong>&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;<strong>Peritoneal abscess (mild-moderate)</strong>&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;<strong>Peritoneal abscess (severe)</strong>&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;<strong>Peritonitis (severe)</strong>&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;<strong>Peritonitis (mild-moderate)</strong>&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;Bacterial pneumonia (Community-acquired pneumonia - severe) [children]&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;Acute malnutrition in infants, children or adolescents (complicated) [children]&lt;br&gt;co-prescribed with gentamicin&lt;br&gt;Sepsis without septic shock&lt;br&gt;Second choice&lt;br&gt;Bacterial meningitis&lt;br&gt;Other indications&lt;br&gt;Bacterial infection of unspecified site</td>
</tr>
</tbody>
</table>
### Anakinra

#### Medicines for juvenile joint diseases
- **Parenteral > General injections > SC:** 100 mg per 0.67 mL in pre-filled syringe

### Anastrozole

#### Hormones and antihormones
- **Oral > Solid:** 1 mg tablet

### Anidulafungin

#### Antifungal medicines
- Therapeutic equivalent to micafungin for
  - Systemic or invasive candidosis

### Anti-d immunoglobulin

#### Human immunoglobulins
- **Parenteral > General injections > IV:** 250 µg in single-dose vial
- **Parenteral > General injections > IM:** 250 µg in single-dose vial

### Anti-rabies immunoglobulin

#### Human immunoglobulins
- **Parenteral > General injections > IM:** 150 IU per mL in vial
- **Parenteral > Locoregional injections > Other:** 150 IU per mL in vial

### Anti-rabies virus monoclonal antibodies

#### Immunologicals > Sera, immunoglobulins and monoclonal antibodies
- **Parenteral > Locoregional injections > Intradermal:** 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Human immunoglobulins</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 500 IU in vial</td>
<td>Tetanus</td>
</tr>
<tr>
<td><strong>Antirabies hyperimmune serum</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 1000 IU in 5 mL ampoule</td>
<td>Rabies</td>
</tr>
<tr>
<td><strong>Antivenom immunoglobulin</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV:</td>
<td>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</td>
</tr>
<tr>
<td><strong>Antivenom sera</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV:</td>
<td>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</td>
</tr>
<tr>
<td><strong>Apixaban</strong></td>
<td></td>
</tr>
<tr>
<td>Medicines affecting coagulation</td>
<td>Therapeutic equivalent to dabigatran for</td>
</tr>
<tr>
<td></td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to dabigatran for</td>
</tr>
<tr>
<td></td>
<td>Other specified atrial fibrillation</td>
</tr>
<tr>
<td><strong>Aprepitant</strong></td>
<td></td>
</tr>
<tr>
<td>Antiemetic medicines</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 125 mg powder for oral suspension (in sachet)</td>
<td>Nausea or vomiting</td>
</tr>
<tr>
<td>Oral &gt; Solid: 80 mg; 125 mg; 165 mg</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Arsenic trioxide</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td><strong>Acute myeloid leukaemia with recurrent genetic abnormalities</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 mg per mL concentrate for solution for infusion</td>
<td></td>
</tr>
</tbody>
</table>

| **Artemether** | |
| **Antimalarial medicines > For curative treatment** | **Malaria due to Plasmodium falciparum** |
| Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection) | **Malaria due to Plasmodium vivax** |

| **Artemether + lumefantrine** | |
| **Antimalarial medicines > For curative treatment** | **Malaria due to Plasmodium falciparum** |
| Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet | **Malaria due to Plasmodium vivax** |

| **Artesunate** | |
| **Antimalarial medicines > For curative treatment** | **Malaria due to Plasmodium falciparum** |
| Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution | **Malaria due to Plasmodium vivax** |
| Oral > Solid: 50 mg tablet | |
| Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules | |

| **Artesunate + amodiaquine** | |
| **Antimalarial medicines > For curative treatment** | **Malaria due to Plasmodium falciparum** |
| Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet | **Malaria due to Plasmodium vivax** |

<p>| <strong>Artesunate + mefloquine</strong> | |
| <strong>Antimalarial medicines &gt; For curative treatment</strong> | <strong>Malaria due to Plasmodium falciparum</strong> |
| Oral &gt; Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet | <strong>Malaria due to Plasmodium vivax</strong> |</p>
<table>
<thead>
<tr>
<th>Artesunate + pyronaridine tetraphosphate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antimalarial medicines &gt; For curative treatment</td>
</tr>
<tr>
<td>Oral &gt; Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Malaria due to Plasmodium falciparum</td>
</tr>
<tr>
<td>Malaria due to Plasmodium vivax</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ascorbic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Vitamins and minerals</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Scurvy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asparaginase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Cytotoxic medicines</td>
</tr>
<tr>
<td>Powder for injection: 10 000 IU in vial.</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 10000 IU in vial powder for injection</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atazanavir</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antiretrovirals &gt; Protease inhibitors</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg (as sulfate); 300 mg (as sulfate)</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atazanavir + ritonavir</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antiretrovirals &gt; Protease inhibitors</td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atenolol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antianginal medicines</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg; 100 mg</td>
</tr>
<tr>
<td>Antihypertensive medicines</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg; 100 mg</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Therapeutic equivalent to bisoprolol for</td>
</tr>
<tr>
<td>Essential hypertension</td>
</tr>
<tr>
<td><strong>Atezolizumab</strong></td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; IV: 1.2 g per 20 mL concentrate solution for infusion</strong></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Atezolizumab</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Atorvastatin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lipid-lowering agents</strong></td>
</tr>
<tr>
<td><strong>Therapeutic equivalent to simvastatin for</strong></td>
</tr>
<tr>
<td>Mixed hyperlipidaemia</td>
</tr>
<tr>
<td><strong>Therapeutic equivalent to simvastatin for</strong></td>
</tr>
<tr>
<td>Coronary atherosclerosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Atracurium</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Muscle relaxants (peripherally-acting) and cholinesterase inhibitors</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; IV: 10 mg per mL (besylate)</strong></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Muscle relaxants</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Atropine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antidotes and other substances used in poisonings &gt; Specific</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; unspecified: 1 mg in 1 mL ampoule (atropine sulfate)</strong></td>
</tr>
<tr>
<td><strong>Preoperative medication and sedation for short-term procedures</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; unspecified: 1 mg in 1 mL ampoule (atropine sulfate)</strong></td>
</tr>
<tr>
<td><strong>Diagnostic agents &gt; Ophthalmic medicines</strong></td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Mydriatics</strong></td>
</tr>
<tr>
<td><strong>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)</strong></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Exposure to or harmful effects of undetermined intent of pesticides</td>
</tr>
<tr>
<td>Parasympatholytics [anticholinergics and antimuscarinics] and spasmyotics</td>
</tr>
<tr>
<td>Therapeutic equivalent to tropicamide for</td>
</tr>
<tr>
<td>Cycloplegic drug</td>
</tr>
<tr>
<td>Anterior uveitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Azacitidine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; IV: 100 mg in vial powder for injection</strong></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Myeloid leukaemia</td>
</tr>
</tbody>
</table>
### Azathioprine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
</table>
| **Disease-modifying anti-rheumatic drugs (DMARDs)** | Rheumatoid arthritis, serology unspecified  
Psoriatic arthritis |
| **Immunomodulators for non-malignant disease** | Failure or rejection of transplanted organs or tissues  
Relapsing-remitting multiple sclerosis |

<table>
<thead>
<tr>
<th>Oral &gt; Solid: 50 mg</th>
</tr>
</thead>
</table>

| Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt) |
| Oral > Solid: 50 mg |

### Azithromycin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ophthalmological preparations &gt; Anti-infective agents</strong></td>
<td>Trachoma</td>
</tr>
</tbody>
</table>
| **Watch group antibiotics** | Chlamydia trachomatis  
Trachoma  
Yaws  
Typhoid fever  
Cholera [children]  
Paratyphoid fever  
Cholera  
Gonococcal infection |
| **First choice** |  
co-prescribed with ceftriaxone  
Gonococcal infection |
| **Second choice** |  
Infectious gastroenteritis or colitis without specification of infectious agent  
co-prescribed with cefixime  
Gonococcal infection |

| Oral > Liquid: 200 mg per 5 mL oral liquid  
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule |

### Aztreonam

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td>Other specified bacterial diseases</td>
</tr>
</tbody>
</table>

<p>| Parenteral &gt; General injections &gt; unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Barium sulfate</strong></td>
<td><strong>Diagnostic agents &gt; Radiocontrast media</strong>&lt;br&gt;Oral &gt; Liquid: Aqueous suspension</td>
</tr>
<tr>
<td><strong>Beclometasone</strong></td>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong>&lt;br&gt;Respiratory &gt; Inhalation &gt; aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)</td>
</tr>
<tr>
<td><strong>Beclometasone + formoterol</strong></td>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong></td>
</tr>
<tr>
<td><strong>Bedaquiline</strong></td>
<td><strong>Antituberculosis medicines</strong>&lt;br&gt;Oral &gt; Solid: 100 mg tablet; 20 mg tablet</td>
</tr>
<tr>
<td><strong>Bendamustine</strong></td>
<td><strong>Cytotoxic medicines</strong>&lt;br&gt;Parenteral &gt; General injections &gt; unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL</td>
</tr>
<tr>
<td><strong>Benzathine benzylpenicillin</strong></td>
<td><strong>Access group antibiotics</strong>&lt;br&gt;Parenteral &gt; General injections &gt; IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)</td>
</tr>
<tr>
<td></td>
<td>Other indications</td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>American trypanosomiasis</strong></td>
<td>Chagas disease</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benzoic acid + salicylic acid</strong></td>
<td>Fungal infection of the skin</td>
</tr>
<tr>
<td>Dermatological medicines &gt; Antifungal medicines</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 6% + 3%</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Ointment: 6% + 3%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benzoyl peroxide</strong></td>
<td>Acne</td>
</tr>
<tr>
<td>Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 5%</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Lotion: 5%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benzyl benzoate</strong></td>
<td>Pthiriasis, Pediculus corporis, Pediculus capitis, Scabies</td>
</tr>
<tr>
<td>Dermatological medicines &gt; Scabicides and pediculicides</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Lotion: 25%</td>
<td></td>
</tr>
</tbody>
</table>
Benzylpenicillin

### Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (≈ 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (≈ 5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (≈ 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (≈ 5 million IU as sodium or potassium salt)

---

### Indications

**First choice**
- Congenital syphilis [children]
- Syphilis
  - co-prescribed with gentamicin
- Acute malnutrition in infants, children or adolescents (complicated) [children]
  - co-prescribed with gentamicin
- Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
  - co-prescribed with gentamicin
- Sepsis without septic shock

**Second choice**
- Bacterial meningitis

**Other indications**
- Bacterial infection of unspecified site

---

Betamethasone

### Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)

---

### Indications

- Pruritus due to skin disorder
- Psoriasis of unspecified type
- Dermatitis or eczema
- Lichen planus

---

Bevacizumab

### Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

---

### Indications

- Age related macular degeneration

---

Bicalutamide

### Hormones and antihormones

Oral > Solid: 50 mg

---

### Indications

- Malignant neoplasms of prostate
### Binimetinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted therapies</strong></td>
<td>Therapeutic equivalent to trametinib for Other specified melanoma of skin</td>
</tr>
</tbody>
</table>

### Biperiden

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for parkinsonism</td>
<td>Parkinson disease</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5 mg per mL in 1 mL ampoule (lactate)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 2 mg tablet (hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>

### Bisacodyl

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laxatives</td>
<td>Therapeutic equivalent to senna for Constipation</td>
</tr>
</tbody>
</table>

### Bisoprolol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antianginal medicines</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Oral &gt; Solid: 1.25 mg; 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicines used in heart failure</th>
<th>Heart failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 1.25 mg; 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antiarrhythmic medicines</th>
<th>Cardiac arrhythmia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 1.25 mg; 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antihypertensive medicines</th>
<th>Essential hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 1.25 mg; 5 mg</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td>Other specified malignant neoplasms of the ovary</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 15 mg in vial (as sulfate)</td>
<td>Germ cell tumour of testis</td>
</tr>
<tr>
<td></td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Hodgkin lymphoma</td>
</tr>
<tr>
<td></td>
<td>Kaposi sarcoma of unspecified primary site</td>
</tr>
<tr>
<td><strong>Bortezomib</strong></td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td><strong>Targeted therapies</strong></td>
<td>Plasma cell myeloma</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 3.5 mg in vial powder for injection</td>
<td></td>
</tr>
<tr>
<td><strong>Bromocriptine</strong></td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td>Parkinson disease</td>
</tr>
<tr>
<td>Oral &gt; Solid: 2.5 mg; 5 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Budesonide</strong></td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong></td>
<td>Asthma</td>
</tr>
<tr>
<td>Respiratory &gt; Inhalation &gt; aerosol: 100 µg per dose; 200 µg per dose</td>
<td></td>
</tr>
<tr>
<td><strong>Ear, nose and throat medicines [c]</strong></td>
<td>Allergic rhinitis</td>
</tr>
<tr>
<td>Local &gt; Nasal &gt; Spray: 100 µg per dose</td>
<td></td>
</tr>
<tr>
<td><strong>Budesonide + formoterol</strong></td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong></td>
<td>Asthma</td>
</tr>
<tr>
<td>Respiratory &gt; Inhalation &gt; dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose</td>
<td></td>
</tr>
<tr>
<td><strong>Budesonide + salmeterol</strong></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--</td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to budesonide + formoterol for Asthma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Bupivacaine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Local anaesthetics</td>
<td>Local anaesthetics</td>
</tr>
<tr>
<td>Parenteral &gt; Locoregional injections &gt; Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Buprenorphine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines for disorders due to psychoactive substance use</td>
<td>Therapeutic equivalent to methadone for Opioid dependence</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Bupropion</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines for disorders due to psychoactive substance use</td>
<td>Nicotine dependence</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg sustained-release (hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>C1 esterase inhibitor</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Plasma-derived medicines</td>
<td>Hereditary angioedema</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 IU in vial powder for injection</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cabergoline</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Antiseizure medicines</td>
<td>Parkinson disease</td>
</tr>
<tr>
<td>Oral &gt; Solid: 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Caffeine citrate</td>
<td>Apnoea of newborn</td>
</tr>
<tr>
<td>Medicines administered to the neonate [c]</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 20 mg per mL (equivalent to 10 mg</td>
<td></td>
</tr>
<tr>
<td>caffeine base per mL)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)</td>
<td></td>
</tr>
<tr>
<td>Calamine</td>
<td></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Anti-inflammatory and antipruritic medicines</td>
<td>Pruritus</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Lotion:</td>
<td></td>
</tr>
<tr>
<td>Calcipotriol</td>
<td></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Medicines affecting skin differentiation and</td>
<td>Psoriasis of unspecified type</td>
</tr>
<tr>
<td>proliferation</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 50 µg per mL (0.005%)</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Lotion: 50 µg per mL (0.005%)</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Ointment: 50 µg per mL (0.005%)</td>
<td></td>
</tr>
<tr>
<td>Calcitriol</td>
<td></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Medicines affecting skin differentiation and</td>
<td></td>
</tr>
<tr>
<td>proliferation</td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to calcipotriol for</td>
<td></td>
</tr>
<tr>
<td>Psoriasis of unspecified type</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td></td>
</tr>
<tr>
<td>Vitamins and minerals</td>
<td>Calcium deficiency</td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg (elemental calcium)</td>
<td></td>
</tr>
</tbody>
</table>
### Calcium folinate (leucovorin calcium)

**Cytotoxic medicines**
- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
- Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet

**Indications**
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Malignant neoplasm metastasis in large intestine
- Malignant trophoblastic neoplasms of placenta
- Burkitt lymphoma including Burkitt leukaemia
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of rectum
- Malignant neoplasms of colon

### Calcium gluconate

**Antidotes and other substances used in poisonings > Specific**
- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

**Vitamins and minerals**
- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

### Canagliflozin

**Oral hypoglycaemic agents**

**Indications**
- Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus

### Capecitabine

**Cytotoxic medicines**
- Oral > Solid: 150 mg tablet; 500 mg tablet

**Indications**
- Malignant neoplasms of colon
- Other specified malignant neoplasms of breast
- Malignant neoplasm metastasis in large intestine
- Malignant neoplasms of rectum

### Capreomycin

**Antituberculosis medicines**
- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

**Indications**
- Multi-drug resistant Mycobacterium tuberculosis
### Captopril

<table>
<thead>
<tr>
<th>Medicines used in heart failure</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td>Heart failure</td>
</tr>
</tbody>
</table>

### Carbachol

<table>
<thead>
<tr>
<th>Ophthalmological preparations &gt; Miotics and antiglaucoma medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic equivalent to pilocarpine for Primary open-angle glaucoma</td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to pilocarpine for Acute angle closure with pupillary block</td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to pilocarpine for Ocular hypertension</td>
<td></td>
</tr>
</tbody>
</table>

### Carbamazepine

<table>
<thead>
<tr>
<th>Antiseizure medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Liquid: 100 mg per 5 mL</td>
<td>Epilepsy or seizures</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable)</td>
<td>Bipolar or related disorders</td>
</tr>
</tbody>
</table>

### Carbetocin

<table>
<thead>
<tr>
<th>Uterotonics</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 µg per mL (heat stable)</td>
<td>Postpartum haemorrhage</td>
</tr>
</tbody>
</table>

### Carbimazole

<table>
<thead>
<tr>
<th>Thyroid hormones and antithyroid medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic equivalent to methimazole for Thyrotoxicosis</td>
<td></td>
</tr>
</tbody>
</table>
### Cytotoxic medicines

**Indications**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other specified gliomas of brain</td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma of bone and articular cartilage of unspecified sites</td>
<td></td>
</tr>
<tr>
<td>Other specified carcinomas of ovary</td>
<td></td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td></td>
</tr>
<tr>
<td>Other specified malignant neoplasms of bronchus or lung</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of nasopharynx</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of kidney, except renal pelvis</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of breast</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of lip, oral cavity or pharynx</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of cervix uteri</td>
<td></td>
</tr>
<tr>
<td>Other specified malignant neoplasms of the ovary</td>
<td></td>
</tr>
<tr>
<td>Germ cell tumour of testis</td>
<td></td>
</tr>
</tbody>
</table>

### Carvedilol

**Section**

**Antianginal medicines**

Therapeutic equivalent to bisoprolol for Angina pectoris

**Medicines used in heart failure**

Therapeutic equivalent to bisoprolol for Heart failure

**Antiarrhythmic medicines**

Therapeutic equivalent to bisoprolol for Cardiac arrhythmia

**Antihypertensive medicines**

Therapeutic equivalent to bisoprolol for Essential hypertension

### Caspofungin

**Section**

**Antifungal medicines**

Therapeutic equivalent to micafungin for Systemic or invasive candidosis
| **Cefalexin** |
|---|---|
| **Access group antibiotics** | **Indications** |
| Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid | First choice |
| Oral > Solid: 250 mg (as monohydrate) | Bacterial cellulitis, erysipelas or lymphangitis |
| Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) | Second choice |
| **Second choice** | Acute pharyngitis |
| Chronic obstructive pulmonary disease with acute exacerbation | Other indications |
| **Other indications** | Bacterial infection of unspecified site |

| **Cefazolin** |
|---|---|
| **Access group antibiotics** | **Indications** |
| Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection | First choice |
| **Other specified prophylactic measures** | Other specified prophylactic measures |
| co-prescribed with metronidazole | Second choice |
| Other specified prophylactic measures | Osteomyelitis or ostelitis |
| **Other indications** | Bacterial infection of joint |
| **Other indications** | Surgical site infection |

| **Cefepime** |
|---|---|
| **Watch group antibiotics** | **Indications** |
| Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection | Other specified bacterial diseases |

<p>| <strong>Cefiderocol</strong> |
|---|---|
| <strong>Reserve group antibiotics</strong> | <strong>Indications</strong> |
| Parenteral &gt; General injections &gt; IV: 1 g in vial (as sulfate toxylate) powder for injection | Carbapenem-resistant Pseudomonas aeruginosa |
| Carbapenem resistant Enterobacterales |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Watch group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 100 mg per 5 mL powder for oral liquid</td>
<td><strong>Second choice</strong>&lt;br&gt;<strong>Infectious gastroenteritis or colitis without specification of infectious agent</strong>&lt;br&gt;co-prescribed with azithromycin&lt;br&gt;Gonococcal infection</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg (as trihydrate): 400 mg (as trihydrate)</td>
<td></td>
</tr>
</tbody>
</table>
### Cefotaxime

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Watch group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 250 mg in vial powder for injection (as sodium salt)</td>
<td></td>
</tr>
<tr>
<td><strong>First choice</strong></td>
<td></td>
</tr>
<tr>
<td>Bacterial meningitis</td>
<td></td>
</tr>
<tr>
<td>Other specified pneumonia (Hospital-acquired pneumonia)</td>
<td></td>
</tr>
<tr>
<td>Bacterial pneumonia (Community-acquired pneumonia - severe) (children)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with amikacin</td>
<td></td>
</tr>
<tr>
<td>Acute pyelonephritis (severe)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with amikacin</td>
<td></td>
</tr>
<tr>
<td>Inflammatory and other diseases of prostate (severe)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with clarithromycin</td>
<td></td>
</tr>
<tr>
<td>Bacterial pneumonia (Community-acquired pneumonia - severe)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with metronidazole</td>
<td></td>
</tr>
<tr>
<td>Peritonitis (severe)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with metronidazole</td>
<td></td>
</tr>
<tr>
<td>Peritoneal abscess (mild-moderate)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with metronidazole</td>
<td></td>
</tr>
<tr>
<td>Peritonitis (mild-moderate)</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with metronidazole</td>
<td></td>
</tr>
<tr>
<td>Peritoneal abscess (severe)</td>
<td></td>
</tr>
<tr>
<td><strong>Second choice</strong></td>
<td></td>
</tr>
<tr>
<td>Osteomyelitis or osteitis</td>
<td></td>
</tr>
<tr>
<td>Acute pyelonephritis (mild to moderate)</td>
<td></td>
</tr>
<tr>
<td>Inflammatory and other diseases of prostate (mild to moderate)</td>
<td></td>
</tr>
<tr>
<td>Bacterial infection of joint</td>
<td></td>
</tr>
<tr>
<td>Sepsis without septic shock</td>
<td></td>
</tr>
<tr>
<td><strong>Other indications</strong></td>
<td></td>
</tr>
<tr>
<td>Bacterial infection of unspecified site</td>
<td></td>
</tr>
</tbody>
</table>

### Ceftaroline

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection</td>
<td></td>
</tr>
</tbody>
</table>
### Ceftazidime

#### Watch group antibiotics

- **Parenteral > General injections > unspecified**: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

#### Indications

- **First choice**
  - co-prescribed with **vancomycin**
    - Endophthalmitis
  - **Other indications**
    - *Pseudomonas aeruginosa* resistant to other antibiotic

### Ceftazidime + avibactam

#### Reserve group antibiotics

- **Parenteral > General injections > IV**: 2 g in vial + 0.5 g in vial powder for injection

#### Indications

- **Carbapenem* Enterobacterales
  - Carbapenem-resistant *Pseudomonas aeruginosa*

### Ceftolozane + tazobactam

#### Reserve group antibiotics

- **Parenteral > General injections > IV**: 1 g + 0.5 g powder for injection

#### Indications

- **Carbapenem-resistant *Pseudomonas aeruginosa***

### Ceftriaxone

#### Watch group antibiotics

- **Parenteral > General injections > unspecified**: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- **Parenteral > General injections > unspecified**: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- **Parenteral > General injections > IV**: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

#### Indications

- **First choice**
  - Typhoid fever
  - Bacterial meningitis
  - Paratyphoid fever
  - **Bacterial pneumonia (Community-acquired pneumonia - severe) [children]**
  - **Other specified pneumonia (Hospital-acquired pneumonia)**
    - co-prescribed with **amikacin**
      - Inflammatory and other diseases of prostate (severe)
      - **Acute pyelonephritis (severe)**
      - co-prescribed with **azithromycin**
      - **Gonococcal infection**
      - co-prescribed with **clarithromycin**
      - **Bacterial pneumonia (Community-acquired pneumonia - severe)**
### Cefuroxime

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Watch group antibiotics</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection</td>
<td></td>
</tr>
</tbody>
</table>

### Cetirizine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiallergics and medicines used in anaphylaxis</td>
<td>Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type</td>
</tr>
</tbody>
</table>
### Chlorambucil

<table>
<thead>
<tr>
<th>Cytotoxic medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 2 mg tablet</td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
</tr>
</tbody>
</table>

### Chloramphenicol

<table>
<thead>
<tr>
<th>Access group antibiotics</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 g in vial powder for injection (sodium succinate)</td>
<td>Second choice</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 500 mg in 2 mL ampoule oily suspension for injection</td>
<td>Bacterial meningitis</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 150 mg per 5 mL (as palmitate)</td>
<td>Other indications</td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg capsule</td>
<td>Bacterial infection of unspecified site</td>
</tr>
</tbody>
</table>

### Chlorhexidine

<table>
<thead>
<tr>
<th>Medicines administered to the neonate [c]</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local &gt; Topical &gt; Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)</td>
<td>Omphalitis of newborn</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)</td>
<td></td>
</tr>
<tr>
<td>Antiseptics</td>
<td>Chlorhexidine</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: 5% (digluconate) for dilution</td>
<td></td>
</tr>
</tbody>
</table>

### Chlorine base compound

<table>
<thead>
<tr>
<th>Disinfectants</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local &gt; Topical &gt; Powder: 0.1% available chlorine for solution</td>
<td>Disinfectant, not elsewhere classified</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Liquid: 0.1% available chlorine for solution</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solid: 0.1% available chlorine for solution</td>
<td></td>
</tr>
</tbody>
</table>
### Chloroquine

**Antimalarial medicines > For chemoprevention**
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)

**Antimalarial medicines > For curative treatment**
- Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)

**Disease-modifying anti-rheumatic drugs (DMARDs)**
- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

### Chlorothiazide

**Antihypertensive medicines**
- Therapeutic equivalent to hydrochlorothiazide for Essential hypertension

**Medicines used in heart failure**
- Therapeutic equivalent to hydrochlorothiazide for Heart failure

### Chloroxylenol

**Disinfectants**
- Local > Topical > Solution: 4.8%
- Phenol disinfectant, not elsewhere classified

### Chlorpromazine

**Medicines for psychotic disorders**
- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
- Schizophrenia or other primary psychotic disorders
### Chlortalidone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive medicines</td>
<td>Therapeutic equivalent to hydrochlorothiazide for Essential hypertension</td>
</tr>
<tr>
<td>Medicines used in heart failure</td>
<td>Therapeutic equivalent to hydrochlorothiazide for Heart failure</td>
</tr>
</tbody>
</table>

### Chlortetracycline

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmological preparations &gt; Anti-infective agents</td>
<td>Therapeutic equivalent to tetracycline for Other specified conjunctivitis</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to tetracycline for Infectious keratitis</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to tetracycline for Trachoma</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to tetracycline for Infectious blepharitis</td>
</tr>
</tbody>
</table>

### Cholera vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for some high-risk populations</td>
<td>Need for immunization against cholera alone</td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td></td>
</tr>
</tbody>
</table>

### Ciclesonide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to budesonide for Asthma</td>
</tr>
</tbody>
</table>

### Ciclosporin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunomodulators for non-malignant disease</td>
<td>Failure or rejection of transplanted organs or tissues</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg per mL in 1 mL ampoule concentrate for injection</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td></td>
</tr>
</tbody>
</table>
### Cimetidine

**Antiulcer medicines**
- Oral > Solid: 200 mg
- Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

**Ciprofloxacin**

**Watch group antibiotics**
- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

**Indications**

- **First choice**
  - Acute pyelonephritis (mild to moderate)
  - Typhoid fever
  - Paratyphoid fever
  - Neutropenia (low-risk)
  - Infectious gastroenteritis or colitis without specification of infectious agent
  - Inflammatory and other diseases of prostate (mild to moderate)

- **Second choice**
  - Cholera [children]
  - Cholera
    - co-prescribed with metronidazole
  - Peritoneal abscess (mild-moderate)
    - co-prescribed with metronidazole
  - Peritonitis (mild-moderate)

- **Other indications**
  - Bacterial infection of unspecified site
  - Infectious diseases of external ear

**Ear, nose and throat medicines [c]**
- Local > Otological > drops: 0.3% (as hydrochloride)
### Cisplatin

**Cytotoxic medicines**

<table>
<thead>
<tr>
<th>Parenteral &gt; General injections &gt; unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL</td>
</tr>
</tbody>
</table>

**Indications**

- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Other specified gliomas of brain
- Malignant neoplasms of nasopharynx
- Malignant neoplasms of cervix uteri
- Other specified malignant neoplasms of the ovary
- Other specified malignant neoplasms of bronchus or lung
- Germ cell tumour of testis
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of lip, oral cavity or pharynx

### Clarithromycin

**Watch group antibiotics**

<table>
<thead>
<tr>
<th>Oral &gt; Solid: 500 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 500 mg in vial powder for injection</td>
</tr>
</tbody>
</table>

**Indications**

- **First choice**
  - co-prescribed with cefotaxime
    - Bacterial pneumonia (Community-acquired pneumonia - severe)
    - Bacterial pneumonia (Community-acquired pneumonia - severe)
  - co-prescribed with ceftriaxone
    - Bacterial pneumonia (Community-acquired pneumonia - severe)

- **Second choice**
  - Acute pharyngitis
  - co-prescribed with amoxicillin + clavulanic acid
    - Bacterial pneumonia (Community-acquired pneumonia - severe)

- **Other indications**
  - Helicobacter pylori associated gastric ulcer
### Clindamycin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 75 mg per 5 mL (as palmitate hydrochloride)</td>
<td>First choice co-prescribed with <strong>piperacillin + tazobactam</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg (as hydrochloride) capsule</td>
<td>NECROTISING FASCIITIS</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 150 mg per mL (as phosphate) injection</td>
<td>SECMD choice</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)</td>
<td>OSTEOMYELITIS OR OSTEITIS</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg (as hydrochloride)</td>
<td>BACTERIAL INFECTION OF JOINT</td>
</tr>
<tr>
<td><strong>Other indications</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Oral > Liquid:** 75 mg per 5 mL (as palmitate hydrochloride)

**Oral > Solid:** 150 mg (as hydrochloride)

**Parenteral > General injections:** unspecified: 150 mg per mL (as phosphate); IV: 150 mg per mL (as phosphate); OSTEOMYELITIS OR OSTEITIS

**BACTERIAL INFECTION OF JOINT**

### Clofazimine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 50 mg</td>
<td>MULTIDRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS</td>
</tr>
<tr>
<td><strong>Antileprosy medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 50 mg</td>
<td>LEPROSY</td>
</tr>
</tbody>
</table>

**Oral > Solid:** 100 mg; 50 mg

### Clomifene

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ovulation inducers</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg (citrate)</td>
<td>FEMALE INFERTILITY WITHOUT SPECIFICATION WHETHER PRIMARY OR SECONDARY</td>
</tr>
</tbody>
</table>

**Oral > Solid:** 50 mg (citrate)

### Clomipramine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for obsessive compulsive disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)</td>
<td>OBSESSIVE-COMPULSIVE DISORDER</td>
</tr>
</tbody>
</table>

**Oral > Solid:** 10 mg (hydrochloride); 25 mg (hydrochloride)

### Clonazepam

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 μg</td>
<td>GENERALISED MYOCLONIC SEIZURE</td>
</tr>
</tbody>
</table>

**Oral > Solid:** 500 μg
### Anti-Platelet Medicines

**Clopidogrel**

**Indications**
- Acute ischaemic heart disease
- Presence of coronary angioplasty implant or graft

**Oral**
- Solid: 75 mg; 300 mg

### Antifungal Medicines

**Clotrimazole**

**Indications**
- Vulvovaginal candidosis

**Local**
- Topical: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

### Access Group Antibiotics

**Cloxacillin**

**Indications**
- **First choice**
  - Bacterial cellulitis, erysipelas or lymphangitis
  - Osteomyelitis or osteitis
  - Bacterial infection of joint
- **Second choice**
  - Co-prescribed with amikacin
  - Sepsis without septic shock
- **Other indications**
  - Bacterial infection of unspecified site

**Oral**
- Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

**Parenteral**
- General injections: unspecified
  - 500 mg in vial (as sodium salt) powder for injection

### Medicines for Psychotic Disorders

**Clozapine**

**Indications**
- Schizophrenia or other primary psychotic disorders

**Oral**
- Solid: 25 mg; 50 mg; 100 mg; 200 mg

### Blood Coagulation Factors

**Coagulation Factor IX**

**Indications**
- Coagulation defects, purpura or other haemorrhagic or related conditions
- Haemophilia B

**Parenteral**
- General injections: IV
  - 500 IU in vial powder for injection; 1000 IU in vial powder for injection
### Coagulation factor VIII

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood coagulation factors</td>
<td>Haemophilia A</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 IU in vial powder for injection</td>
<td></td>
</tr>
</tbody>
</table>

### Coal tar

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</td>
<td>Psoriasis of unspecified type</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: 5%</td>
<td></td>
</tr>
</tbody>
</table>

### Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</td>
<td></td>
</tr>
</tbody>
</table>

### Cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg + 150 mg + 200 mg + 10 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Cobimetinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
<td>Therapeutic equivalent to trametinib for Other specified melanoma of skin</td>
</tr>
</tbody>
</table>

### Codeine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid analgesics</td>
<td>Pain</td>
</tr>
<tr>
<td>Oral &gt; Solid: 30 mg tablet (codeine phosphate)</td>
<td></td>
</tr>
<tr>
<td>Antitussives</td>
<td>Cough</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet (codeine phosphate)</td>
<td></td>
</tr>
<tr>
<td>Medicines for diarrhoea</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Oral &gt; Solid: 30 mg tablet (codeine phosphate)</td>
<td></td>
</tr>
</tbody>
</table>
### Colchicine

**Medicines used to treat gout**
- Oral > Solid: 0.5 mg

### Colecalciferol

**Vitamins and minerals**
- Oral > Liquid: 400 IU per mL
- Oral > Solid: 400 IU; 1000 IU

**Indications**
- Calcium deficiency
- Vitamin D deficiency
- Therapeutic equivalent to ergocalciferol for Calcium deficiency
- Therapeutic equivalent to ergocalciferol for Vitamin D deficiency

### Colistin (injection)

**Reserve group antibiotics**
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)

**Indications**
- Other specified bacterial diseases
- Carbapenem resistant Acinetobacter baumannii
- Carbapenem-resistant Pseudomonas aeruginosa
- Carbapenem resistant Enterobacterales

### Compound sodium lactate solution

**Solutions correcting water, electrolyte and acid-base disturbances**
- Parenteral > General injections > IV: injectable solution

**Indications**
- Other specified disorders of fluid, electrolyte or acid-base balance
- Hypovolaemic shock

### Condoms

**Barrier methods**

**Indications**
- Contact with health services for contraceptive management
### Copper-containing intrauterine device

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrauterine devices</td>
<td>Contact with health services for insertion of contraceptive device</td>
</tr>
</tbody>
</table>

### Crizotinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 250 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Cyanocobalamin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antianaemia medicines</td>
<td>Anaemias or other erythrocyte disorders</td>
</tr>
</tbody>
</table>

### Cyclizine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 50 mg per mL</td>
<td></td>
</tr>
</tbody>
</table>

### Cyclopentolate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic agents &gt; Ophthalmic medicines</td>
<td>Therapeutic equivalent to tropicamide for</td>
</tr>
<tr>
<td></td>
<td>Cycloplegic drug</td>
</tr>
<tr>
<td>Ophthalmological preparations &gt; Mydriatics</td>
<td>Therapeutic equivalent to atropine for</td>
</tr>
<tr>
<td></td>
<td>Anterior uveitis</td>
</tr>
</tbody>
</table>
### Cyclophosphamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg tablet</td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 500 mg in vial powder for injection</td>
<td>Malignant trophoblastic neoplasms of placenta</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 g in vial powder for injection; 2 g in vial powder for injection</td>
<td>Follicular lymphoma</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg tablet; 50 mg tablet</td>
<td>Burkitt lymphoma including Burkitt leukaemia</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Ewing sarcoma of bone and articular cartilage of unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td></td>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
</tr>
<tr>
<td></td>
<td>Diffuse large B-cell lymphomas</td>
</tr>
<tr>
<td></td>
<td>Plasma cell myeloma</td>
</tr>
<tr>
<td></td>
<td>Other specified gliomas of brain</td>
</tr>
<tr>
<td></td>
<td>Other specified malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of kidney, except renal pelvis</td>
</tr>
<tr>
<td></td>
<td>Rhabdomyosarcoma primary site</td>
</tr>
<tr>
<td></td>
<td>Hodgkin lymphoma</td>
</tr>
</tbody>
</table>

### Cycloserine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg; 125 mg</td>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
</tbody>
</table>

### Cytarabine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 100 mg in vial powder for injection</td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Acute myeloid leukaemia with recurrent genetic abnormalities</td>
</tr>
<tr>
<td></td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td></td>
<td>Myeloid leukaemia</td>
</tr>
<tr>
<td></td>
<td>Burkitt lymphoma including Burkitt leukaemia</td>
</tr>
</tbody>
</table>
### Dabigatran

<table>
<thead>
<tr>
<th>Medicines affecting coagulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 110 mg; 150 mg</td>
<td>- Venous thromboembolism</td>
</tr>
<tr>
<td></td>
<td>- Other specified atrial fibrillation</td>
</tr>
</tbody>
</table>

### Dabrafenib

<table>
<thead>
<tr>
<th>Targeted therapies</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 50 mg; 75 mg</td>
<td>- Other specified melanoma of skin</td>
</tr>
</tbody>
</table>

### Dacarbazine

<table>
<thead>
<tr>
<th>Cytotoxic medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg in vial powder for injection</td>
<td>- Hodgkin lymphoma</td>
</tr>
</tbody>
</table>

### Daclatasvir

<table>
<thead>
<tr>
<th>Medicines for hepatitis C &gt; Pangenotypic direct-acting antiviral combinations</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)</td>
<td>- Chronic hepatitis C</td>
</tr>
</tbody>
</table>

### Daclatasvir + sofosbuvir

<table>
<thead>
<tr>
<th>Medicines for hepatitis C &gt; Pangenotypic direct-acting antiviral combinations</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 60 mg + 400 mg</td>
<td>- Chronic hepatitis C</td>
</tr>
</tbody>
</table>

### Dactinomycin

<table>
<thead>
<tr>
<th>Cytotoxic medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 µg in vial powder for injection</td>
<td>- Malignant trophoblastic neoplasms of placenta</td>
</tr>
<tr>
<td></td>
<td>- Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>- Malignant neoplasms of kidney, except renal pelvis</td>
</tr>
<tr>
<td></td>
<td>- Rhabdomyosarcoma primary site</td>
</tr>
<tr>
<td></td>
<td>- Ewing sarcoma of bone and articular cartilage of unspecified sites</td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Medicines affecting coagulation</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to enoxaparin for</td>
<td></td>
</tr>
<tr>
<td><em>Acute ischaemic heart disease</em></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to enoxaparin for</td>
<td></td>
</tr>
<tr>
<td><em>Venous thromboembolism</em></td>
<td></td>
</tr>
<tr>
<td><strong>Dalteparin</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Dapagliflozin</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to empagliflozin for</td>
<td></td>
</tr>
<tr>
<td><em>Type 2 diabetes mellitus</em></td>
<td></td>
</tr>
<tr>
<td><strong>Dapsone</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antileprosy medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet</td>
<td><strong>Leprosy</strong></td>
</tr>
<tr>
<td><strong>Daptomycin</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection</td>
<td><strong>Other specified bacterial diseases</strong></td>
</tr>
<tr>
<td><strong>Daratumumab</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg per 5 mL; 400 mg per 20 mL</td>
<td><strong>Plasma cell myeloma</strong></td>
</tr>
<tr>
<td><strong>Darbepoetin alfa</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antanaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to erythropoiesis-stimulating agents for</td>
<td><strong>Anaemia due to chronic disease</strong></td>
</tr>
</tbody>
</table>
### Darunavir

**Indications**

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

### Dasabuvir

**Indications**

Chronic hepatitis C

### Dasatinib

**Indications**

Chronic myeloid leukaemia, not elsewhere classified

### Daunorubicin

**Indications**

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

### Deferoxamine

**Indications**

Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies
### Delafloxacin

#### Section

**Watch group antibiotics**

Parenteral > General injections > IV: 300 mg lyophilized powder for injection  
Oral > Solid: 450 mg  

#### Indications

Methicillin resistant Staphylococcus aureus

### Delamanid

#### Section

**Antituberculosis medicines**

Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)

#### Indications

Multi-drug resistant Mycobacterium tuberculosis

### Dengue vaccine

#### Section

**Recommendations for some high-risk populations**

All vaccines should comply with the WHO requirements for biological substances.

#### Indications

Need for immunization against certain single viral diseases

### Desmopressin

#### Section

**Medicines affecting coagulation**

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)  
Local > Nasal > Spray: 10 µg per dose (acetate)

#### Indications

Haemophilia A  
Von Willebrand disease
### Dexamethasone

#### Other medicines administered to the mother
- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

#### Hormones and antihormones
- Oral: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
- Oral: 2 mg per 5 mL
- Oral: 2 mg; 4 mg

#### Medicines for other common symptoms in palliative care
- Oral: 2 mg per 5 mL
- Oral: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

#### Antiallergics and medicines used in anaphylaxis
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

#### Antiemetic medicines
- Oral: 0.5 mg per 5 mL; 2 mg per 5 mL
- Oral: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

### Dextran 40

#### Plasma substitutes
- Hypovolaemia

### Dextran 70

#### Plasma substitutes
- Hypovolaemia
### Diaphragms

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrier methods</td>
<td>Contact with health services for contraceptive management</td>
</tr>
</tbody>
</table>

### Diazepam

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiseizure medicines</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes</td>
<td></td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 2 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg; 10 mg</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Solution: 2.5 mg; 5 mg; 10 mg</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 5 mg per mL</td>
<td></td>
</tr>
<tr>
<td>Medicines for anxiety disorders</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg (scored); 2 mg (scored)</td>
<td></td>
</tr>
</tbody>
</table>

### Diazoxide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for hypoglycaemia</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per mL</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Didanosine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule</td>
<td></td>
</tr>
</tbody>
</table>
### Diethylcarbamazine

#### Antifilarials

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphatic filariasis</td>
</tr>
</tbody>
</table>

Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

### Digitoxin

#### Medicines used in heart failure

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
</tr>
</tbody>
</table>

Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule

Oral > Solid: 50 µg; 100 µg

### Digoxin

#### Antiarrhythmic medicines

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac arrhythmia</td>
</tr>
</tbody>
</table>

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid: 62.5 µg; 250 µg

#### Medicines used in heart failure

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
</tr>
</tbody>
</table>

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid: 62.5 µg; 250 µg

### Dihydroartemisinin + piperaquine phosphate

#### Antimalarial medicines > For curative treatment

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria due to Plasmodium falciparum</td>
</tr>
<tr>
<td>Malaria due to Plasmodium vivax</td>
</tr>
</tbody>
</table>

Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet

### Dihydroergocryptine mesylate

#### Antiseizure medicines

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson disease</td>
</tr>
</tbody>
</table>

Oral > Solid:

### Diloxanide

#### Antiamoebic and anti giardiasis medicines

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoebiasis</td>
</tr>
</tbody>
</table>

Oral > Solid: 500 mg (furoate)
### Dimercaprol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Specific Parenteral &gt; General injections &gt; IM: 50 mg per mL in 2 mL ampoule</td>
<td>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</td>
</tr>
</tbody>
</table>

### Diphtheria antitoxin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunologicals &gt; Sera, immunoglobulins and monoclonal antibodies Parenteral &gt; General injections IM: 10000 IU in vial; 20000 IU in vial</td>
<td>Need for immunization against diphtheria alone</td>
</tr>
</tbody>
</table>

### Diphtheria vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against diphtheria alone</td>
</tr>
</tbody>
</table>

### Diphtheria-pertussis-tetanus vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against diphtheria-tetanus-pertussis, combined</td>
</tr>
</tbody>
</table>

### Diphtheria-tetanus vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for all immunization programmes All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against combinations of infectious diseases</td>
</tr>
</tbody>
</table>

### Docetaxel

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines Parenteral &gt; General injections IV: 20 mg per mL; 40 mg per mL</td>
<td>Malignant neoplasms of breast Malignant neoplasms of prostate Other specified malignant neoplasms of breast Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td><strong>Docusate sodium</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per 5 mL oral liquid</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg capsule</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dolasetron</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Antiemetic medicines</td>
<td>Therapeutic equivalent to ondansetron for Nausea or vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dolutegravir</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Antiretrovirals &gt; Integrase inhibitors</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dolutegravir + lamivudine + tenofovir</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dopamine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines used in heart failure</td>
<td>Heart failure</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 40 mg per mL in 5 mL vial (hydrochloride)</td>
<td>Cardiogenic shock</td>
</tr>
</tbody>
</table>
## Doxorubicin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td><em>Unspecified malignant neoplasms of ill-defined or unspecified sites</em></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)</td>
<td><em>Rhabdomyosarcoma primary site</em></td>
</tr>
<tr>
<td></td>
<td><em>Follicular lymphoma</em></td>
</tr>
<tr>
<td></td>
<td><em>Burkitt lymphoma including Burkitt leukaemia</em></td>
</tr>
<tr>
<td></td>
<td><em>Malignant neoplasms of breast</em></td>
</tr>
<tr>
<td></td>
<td><em>Ewing sarcoma of bone and articular cartilage of unspecified sites</em></td>
</tr>
<tr>
<td></td>
<td><em>Lymphoid leukaemia, not elsewhere classified</em></td>
</tr>
<tr>
<td></td>
<td><em>Other specified malignant neoplasms of breast</em></td>
</tr>
<tr>
<td></td>
<td><em>Hodgkin lymphoma</em></td>
</tr>
<tr>
<td></td>
<td><em>Diffuse large B-cell lymphomas</em></td>
</tr>
<tr>
<td></td>
<td><em>Plasma cell myeloma</em></td>
</tr>
<tr>
<td></td>
<td><em>Malignant neoplasms of kidney, except renal pelvis</em></td>
</tr>
<tr>
<td></td>
<td><em>Osteosarcoma of bone and articular cartilage of unspecified sites</em></td>
</tr>
<tr>
<td></td>
<td><em>Kaposi sarcoma of unspecified primary site</em></td>
</tr>
</tbody>
</table>

## Doxycycline

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access group antibiotics</td>
<td><em>First choice</em></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg (as hyclate)</td>
<td><em>Cholera</em></td>
</tr>
<tr>
<td></td>
<td><em>Chlamydia trachomatis</em></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 100 mg in vial powder for injection</td>
<td><em>Second choice</em></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)</td>
<td><em>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</em></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg (as hyclate); 50 mg (as hyclate)</td>
<td><em>Cholera [children]</em></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg (as hyclate); 100 mg (as hyclate)</td>
<td><em>Chronic obstructive pulmonary disease with acute exacerbation</em></td>
</tr>
<tr>
<td></td>
<td><em>Other indications</em></td>
</tr>
<tr>
<td></td>
<td><em>Bacterial infection of unspecified site</em></td>
</tr>
<tr>
<td>Antimalarial medicines &gt; For chemoprevention</td>
<td><em>Malaria due to Plasmodium falciparum</em></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg (hydrochloride or hyclate)</td>
<td></td>
</tr>
<tr>
<td>Antimalarial medicines &gt; For curative treatment</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)</td>
<td></td>
</tr>
</tbody>
</table>
### Durvalumab

**Immunomodulators**

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung</td>
</tr>
</tbody>
</table>

### Edoxaban

**Medicines affecting coagulation**

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic equivalent to dabigatran for Venous thromboembolism</td>
</tr>
<tr>
<td>Therapeutic equivalent to dabigatran for Other specified atrial fibrillation</td>
</tr>
</tbody>
</table>

### Efavirenz

**Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors**

<table>
<thead>
<tr>
<th>Oral &gt; Solid: 600 mg tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
</tbody>
</table>

### Efavirenz + emtricitabine + tenofovir

**Fixed-dose combinations of antiretrovirals**

<table>
<thead>
<tr>
<th>Oral &gt; Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
</tbody>
</table>

### Efavirenz + lamivudine + tenofovir

**Fixed-dose combinations of antiretrovirals**

<table>
<thead>
<tr>
<th>Oral &gt; Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for</td>
</tr>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td><strong>Eflornithine</strong></td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines for the treatment of 2nd stage African trypanosomiasis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 200 mg per mL in 100 mL bottle (hydrochloride)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Elbasvir + grazoprevir</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Medicines for hepatitis C &gt; Non-pangenotypic direct-acting antiviral combinations</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg + 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Empagliflozin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Oral hypoglycaemic agents</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg; 25 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Emtricitabine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 10 mg per mL</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emtricitabine + rilpivirine + tenofovir alafenamide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg + 25 mg + 25 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emtricitabine + rilpivirine + tenofovir disoproxil fumarate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</td>
</tr>
</tbody>
</table>
### Emtricitabine + tenofovir

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td><strong>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</td>
<td><strong>Contact with or exposure to human immunodeficiency virus</strong></td>
</tr>
</tbody>
</table>

### Emtricitabine + tenofovir alafenamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td><strong>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg + 10 mg; 200 mg + 25 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Enalapril

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive medicines</td>
<td><strong>Essential hypertension</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)</td>
<td></td>
</tr>
<tr>
<td>Medicines used in heart failure</td>
<td><strong>Heart failure</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)</td>
<td></td>
</tr>
</tbody>
</table>

### Encorafenib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
<td><strong>Therapeutic equivalent to dabrafenib for</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Other specified melanoma of skin</strong></td>
</tr>
</tbody>
</table>
### Enoxaparin

**Medicines affecting coagulation**

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule.

#### Indications

- Acute ischaemic heart disease
- Venous thromboembolism

### Entecavir

**Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors**

Oral > Liquid: 0.05 mg per mL
Oral > Solid: 0.5 mg; 1 mg

#### Indications

- Chronic hepatitis B

### Enzalutamide

**Hormones and antihormones**

Oral > Solid: 40 mg

#### Indications

- Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate
- Malignant neoplasms of prostate

### Ephedrine

**Local anaesthetics**

Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

#### Indications

- Cardiac complications of anaesthesia during labour or delivery
<table>
<thead>
<tr>
<th><strong>Epinephrine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiarrhythmic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)</td>
<td>Cardiac arrest</td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Mydriatics</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 2% (as hydrochloride)</td>
<td>Primary open-angle glaucoma</td>
</tr>
<tr>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)</td>
<td>Asthma</td>
</tr>
<tr>
<td><strong>Antiallergics and medicines used in anaphylaxis</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td></td>
<td>Anaphylaxis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Epoetin alfa</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antianaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Epoetin beta</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antianaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Epoetin theta</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antianaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Equine rabies immunoglobulin</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunologicals &gt; Sera, immunoglobulins and monoclonal antibodies</td>
<td>Rabies</td>
</tr>
<tr>
<td>Parenteral &gt; Locoregional injections &gt; Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg lyophilized powder for injection</td>
<td><strong>Carbapenem resistant Enterobacterales</strong></td>
</tr>
<tr>
<td><strong>Erovacycline</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Ergocalciferol</strong></td>
<td></td>
</tr>
<tr>
<td>Vitamins and minerals</td>
<td>Therapeutic equivalent to colecalciferol for Calcium deficiency</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 250 µg per mL (10 000 IU per mL)</td>
<td>Vitamin D deficiency</td>
</tr>
<tr>
<td>Oral &gt; Solid: 1.25 mg (50 000 IU)</td>
<td>Calcium deficiency</td>
</tr>
<tr>
<td><strong>Ergometrine</strong></td>
<td></td>
</tr>
<tr>
<td>Uterotonics</td>
<td>Postpartum haemorrhage</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)</td>
<td></td>
</tr>
<tr>
<td><strong>Erlotinib</strong></td>
<td></td>
</tr>
<tr>
<td>Targeted therapies</td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 150 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Erythromycin</strong></td>
<td></td>
</tr>
<tr>
<td>Watch group antibiotics</td>
<td>Bacterial infection of unspecified site</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 mg in vial powder for injection</td>
<td>Chlamydial conjunctivitis</td>
</tr>
<tr>
<td>(as lactobionate)</td>
<td>Gonococcal infection of eye</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg (as stearate or ethylsuccinate)</td>
<td></td>
</tr>
<tr>
<td>Ophthalmological preparations &gt; Anti-infective agents</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Ointment: 0.5%</td>
<td></td>
</tr>
</tbody>
</table>
### Erythropoiesis-stimulating agents

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antinaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 1000 IU per 0.5 mL pre-</td>
<td>Anaemia due to chronic disease</td>
</tr>
<tr>
<td>filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3</td>
<td></td>
</tr>
<tr>
<td>mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU</td>
<td></td>
</tr>
<tr>
<td>per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe;</td>
<td></td>
</tr>
<tr>
<td>8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled</td>
<td></td>
</tr>
<tr>
<td>syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-</td>
<td></td>
</tr>
<tr>
<td>filled syringe</td>
<td></td>
</tr>
</tbody>
</table>

### Estradiol cypionate + medroxyprogesterone acetate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Injectable hormonal contraceptives</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 5 mg + 25 mg</td>
<td>Contact with health services for reasons associated</td>
</tr>
<tr>
<td></td>
<td>with reproduction</td>
</tr>
</tbody>
</table>

### Ethambutol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 25 mg per mL</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg</td>
<td>Other specified tuberculosis</td>
</tr>
<tr>
<td>tablet (dispersible)</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1000 mg per 10 mL; 2000 mg per 20</td>
<td></td>
</tr>
<tr>
<td>mL</td>
<td></td>
</tr>
</tbody>
</table>

### Ethambutol + isoniazid

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg + 150 mg tablet</td>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>

### Ethambutol + isoniazid + pyrazinamide + rifampicin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet</td>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>

### Ethambutol + isoniazid + rifampicin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 275 mg + 75 mg + 150 mg tablet</td>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>
# Antiseptics

**Local > Topical > Solution:** 70% (denatured)

## Ethanol

**Indications:**
- Denatured alcohol

## Ether

**Indications:**
- Anaesthetics and therapeutic gases

## Ethinylestradiol + etonogestrel

**Indications:**
- Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

**Indications:**
- Contact with health services for contraceptive management
- Contact with health services for postcoital contraception

## Ethinylestradiol + norethisterone

**Indications:**
- Contact with health services for contraceptive management

## Ethionamide

**Indications:**
- Multi-drug resistant Mycobacterium tuberculosis

## Ethosuximide

**Indications:**
- Absence seizures, typical
### Implantable contraceptives

- **Etonogestrel-releasing implant**
  - Implant > Subdermal: 68 mg single rod

### Cytotoxic medicines

#### Etoposide

- **Parenteral** > General injections > IV: 20 mg per mL in 5 mL ampoule
- **Oral** > Solid: 100 mg capsule
- **Oral** > Solid: 100 mg capsule; 50 mg capsule

### Targeted therapies

- **Everolimus**
  - Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)

### Opioid analgesics

- **Fentanyl**
  - Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ferrous salt</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antianaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 25 mg per mL iron (as sulfate)</td>
<td>Iron deficiency anaemia</td>
</tr>
<tr>
<td>Oral &gt; Solid: 60 mg iron</td>
<td></td>
</tr>
<tr>
<td><strong>Ferrous salt + folic acid</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antianaemia medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 60 mg iron + 400 µg tablet</td>
<td>Clefts of lip, alveolus or palate</td>
</tr>
<tr>
<td></td>
<td>Iron deficiency anaemia</td>
</tr>
<tr>
<td></td>
<td>Anencephaly or similar anomalies</td>
</tr>
<tr>
<td></td>
<td>Spina bifida</td>
</tr>
<tr>
<td><strong>Fexinidazole</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Medicines for the treatment of 1st stage African trypanosomiasis</strong></td>
<td>African trypanosomiasis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 600 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Medicines for the treatment of 2nd stage African trypanosomiasis</strong></td>
<td>African trypanosomiasis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 600 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Fexofenadine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antiallergics and medicines used in anaphylaxis</strong></td>
<td>Therapeutic equivalent to loratadine for</td>
</tr>
<tr>
<td></td>
<td>Allergic or hypersensitivity conditions of unspecified type</td>
</tr>
<tr>
<td><strong>Fifth generation cephalosporins</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td>Other specified bacterial diseases</td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial</td>
<td>Acquired neutropaenia</td>
</tr>
<tr>
<td><strong>Fingolimod</strong></td>
<td></td>
</tr>
<tr>
<td>Immunomodulators for non-malignant disease</td>
<td>Relapsing-remitting multiple sclerosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 0.25 mg; 0.5 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Fluconazole</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antifungal medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 2 mg per mL in vial</td>
<td>Cryptococcosis</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per 5 mL</td>
<td>Candidosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg capsule</td>
<td></td>
</tr>
<tr>
<td><strong>Flucytosine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antifungal medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 2.5 g per 250 mL infusion</td>
<td>Cryptococcosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg capsule</td>
<td></td>
</tr>
<tr>
<td><strong>Fludarabine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg in vial (fludarabine phosphate) powder for injection</td>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet (fludarabine phosphate)</td>
<td></td>
</tr>
<tr>
<td><strong>Fludrocortisone</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Adrenal hormones and synthetic substitutes</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 µg (acetate)</td>
<td>Adrenocortical insufficiency</td>
</tr>
</tbody>
</table>
**Flunisolide**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to budesonide for Asthma</td>
</tr>
</tbody>
</table>

**Fluorescein**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic agents &gt; Ophthalmic medicines</td>
<td>Fluorescein</td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 1% (sodium salt)</td>
<td></td>
</tr>
</tbody>
</table>

**Fluoride**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dental medicines and preparations</td>
<td>Dental caries</td>
</tr>
<tr>
<td>Local &gt; Dental &gt; Paste: 1000 to 1500 ppm fluoride (any type)</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Dental &gt; Cream: 1000 to 1500 ppm fluoride (any type)</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Dental &gt; Gel: 1000 to 1500 ppm fluoride (any type)</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Dental &gt; Other: In other appropriate topical formulations</td>
<td></td>
</tr>
</tbody>
</table>

**Fluorouracil**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg per mL in 5 mL ampoule</td>
<td></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</td>
<td>Plantar warts</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Ointment: 5%</td>
<td></td>
</tr>
<tr>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of nasopharynx</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasm metastasis in large intestine</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of rectum</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of colon</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>Medicines for depressive disorders</td>
<td>Depressive disorders</td>
</tr>
<tr>
<td>Oral &gt; Solid: 20 mg (as hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
<td>Palliative care</td>
</tr>
<tr>
<td>Oral &gt; Solid: 20 mg (as hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for psychotic disorders</td>
<td>Schizophrenia or other primary psychotic disorders</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormones and antihormones</td>
<td>Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to budesonide for Asthma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to budesonide + formoterol for Asthma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to budesonide + formoterol for Asthma</td>
</tr>
</tbody>
</table>
### Fluvastatin

**Lipid-lowering agents**

Therapeutic equivalent to simvastatin for:

- Mixed hyperlipidaemia
- Coronary atherosclerosis

### Folic acid

**Antiaemia medicines**

<table>
<thead>
<tr>
<th>Oral</th>
<th>Solid: 1 mg tablet; 5 mg tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Solid: 400 µg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folate deficiency anaemia</td>
</tr>
<tr>
<td>Cephalocele</td>
</tr>
<tr>
<td>Anencephaly or similar anomalies</td>
</tr>
<tr>
<td>Spina bifida</td>
</tr>
</tbody>
</table>

### Fomepizole

**Antidotes and other substances used in poisonings > Specific**

Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</td>
</tr>
</tbody>
</table>

### Fosfomycin (injection)

**Reserve group antibiotics**

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other specified bacterial diseases</td>
</tr>
<tr>
<td>Carbapenem-resistant Pseudomonas aeruginosa</td>
</tr>
<tr>
<td>Carbapenem resistant Enterobacterales</td>
</tr>
</tbody>
</table>

### Fourth generation cephalosporins

**Watch group antibiotics**

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other specified bacterial diseases</td>
</tr>
</tbody>
</table>

### Fresh-frozen plasma

**Blood and blood components**

Parenteral > General injections > IV:

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion without reported diagnosis</td>
</tr>
</tbody>
</table>
### Fulvestrant

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormones and antihormones</td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 250 mg per 5 mL</td>
<td></td>
</tr>
</tbody>
</table>

### Furosemide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines used in heart failure</td>
<td>Heart failure</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 2 mL ampoule</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg per 5 mL</td>
<td>Anuria or oliguria</td>
</tr>
<tr>
<td>Oral &gt; Solid: 40 mg</td>
<td>Oedema</td>
</tr>
<tr>
<td>Diuretics</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 2 mL ampoule</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 40 mg; 10 mg; 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Gabapentin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)</td>
<td>Neuropathic pain</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Gallamine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle relaxants (peripherally-acting) and cholinesterase inhibitors</td>
<td>Muscle relaxants</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)</td>
<td></td>
</tr>
</tbody>
</table>

### Gatifloxacin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antituberculosis medicines</td>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 400 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Gefitinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
<td>Therapeutic equivalent to erlotinib for</td>
</tr>
<tr>
<td></td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
</tbody>
</table>
## Gemcitabine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td>Other specified carcinomas of ovary</td>
</tr>
<tr>
<td></td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 200 mg in vial powder for injection; 1 g in vial powder for injection</td>
<td></td>
</tr>
</tbody>
</table>

## Gentamicin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access group antibiotics</td>
<td>First choice</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)</td>
<td>Neonatal meningitis</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with amoxicillin</td>
</tr>
<tr>
<td></td>
<td>Sepsis without septic shock</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with amoxicillin</td>
</tr>
<tr>
<td></td>
<td>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Peritoneal abscess (mild-moderate)</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Peritoneal abscess (severe)</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Peritonitis (severe)</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Sepsis without septic shock</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Peritonitis (mild-moderate)</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with ampicillin</td>
</tr>
<tr>
<td></td>
<td>Acute malnutrition in infants, children or adolescents (complicated) [children]</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with benzylpenicillin</td>
</tr>
<tr>
<td></td>
<td>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with benzylpenicillin</td>
</tr>
<tr>
<td></td>
<td>Acute malnutrition in infants, children or adolescents (complicated) [children]</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with benzylpenicillin</td>
</tr>
<tr>
<td></td>
<td>Sepsis without septic shock</td>
</tr>
<tr>
<td></td>
<td>co-prescribed with benzylpenicillin</td>
</tr>
<tr>
<td></td>
<td>Other specified prophylactic measures</td>
</tr>
<tr>
<td></td>
<td>Gonococcal infection</td>
</tr>
</tbody>
</table>
### Other indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial infection of unspecified site</td>
</tr>
<tr>
<td>Other specified conjunctivitis</td>
</tr>
<tr>
<td>Infectious blepharitis</td>
</tr>
</tbody>
</table>

### Glass ionomer cement

#### Section

**Dental medicines and preparations**

#### Indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dental caries</td>
</tr>
</tbody>
</table>

### Glatiramer acetate

#### Section

**Immunomodulators for non-malignant disease**

#### Indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapsing-remitting multiple sclerosis</td>
</tr>
</tbody>
</table>

### Glecaprevir + pibrentasvir

#### Section

**Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations**

#### Indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic hepatitis C</td>
</tr>
</tbody>
</table>

### Glibenclamide

#### Section

**Oral hypoglycaemic agents**

#### Indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 diabetes mellitus</td>
</tr>
</tbody>
</table>

### Gliclazide

#### Section

**Oral hypoglycaemic agents**

#### Indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 diabetes mellitus</td>
</tr>
</tbody>
</table>

### Glucagon

#### Section

**Medicines for hypoglycaemia**

#### Indications

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycaemia in the context of diabetes</td>
</tr>
</tbody>
</table>
### Glucose

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solutions correcting water, electrolyte and acid-base disturbances &gt;</td>
<td>Other specified disorders of fluid, electrolyte or acid-base balance</td>
</tr>
<tr>
<td>Parenteral</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5% isotonic; 10% hypertonic</td>
<td>Hypoglycaemia without associated diabetes</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50% hypertonic</td>
<td></td>
</tr>
</tbody>
</table>

### Glucose + sodium chloride

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solutions correcting water, electrolyte and acid-base disturbances &gt;</td>
<td>Other specified disorders of fluid, electrolyte or acid-base balance</td>
</tr>
<tr>
<td>Parenteral</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 4% + 0.18% (equivalent to Na+ 30</td>
<td></td>
</tr>
<tr>
<td>mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)</td>
<td></td>
</tr>
</tbody>
</table>

### Glutaral

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disinfectants</td>
<td>Glutaral nonmedicinal</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: 2%</td>
<td></td>
</tr>
</tbody>
</table>

### Glyceryl trinitrate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antianginal medicines</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 µg sublingual tablet</td>
<td></td>
</tr>
</tbody>
</table>

### Glycopyrronium

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease</td>
</tr>
</tbody>
</table>

### Goserelin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormones and antihormones</td>
<td>Therapeutic equivalent to leuprolein for Malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to leuprolein for Malignant neoplasms of prostate</td>
</tr>
</tbody>
</table>
### Granisetron

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for other common symptoms in palliative care</strong></td>
<td>Therapeutic equivalent to ondansetron for Palliative care</td>
</tr>
</tbody>
</table>

**Antiemetic medicines**

Therapeutic equivalent to ondansetron for Nausea or vomiting

### Griseofulvin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungal medicines</strong></td>
<td>Dermatophytosis</td>
</tr>
</tbody>
</table>

**Oral**
- Liquid: 125 mg per 5 mL
- Solid: 125 mg; 250 mg

### Haemophilus influenzae type b vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendations for all immunization programmes</strong></td>
<td>Need for immunization against single bacterial diseases</td>
</tr>
</tbody>
</table>

All vaccines should comply with the WHO requirements for biological substances.

### Haloperidol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for other common symptoms in palliative care</strong></td>
<td>Palliative care</td>
</tr>
</tbody>
</table>

**Oral**
- Liquid: 2 mg per mL
- Solid: 0.5 mg; 2 mg; 5 mg

**Parenteral**
- General injections > unspecified: 5 mg per mL in 1-mL ampoule

**Medicines for psychotic disorders**

**Oral**
- Liquid: 2 mg per mL
- Solid: 2 mg; 0.5 mg; 5 mg

### Halothane

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General anaesthetics and oxygen &gt; Inhalational medicines</strong></td>
<td>Anaesthetics and therapeutic gases</td>
</tr>
</tbody>
</table>

**Respiratory**
- Inhalation > liquid:
## Medicines affecting coagulation

### Heparin sodium

<table>
<thead>
<tr>
<th>Parenteral &gt; General injections &gt; IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Acute ischaemic heart disease</td>
</tr>
<tr>
<td>Unstable angina</td>
</tr>
<tr>
<td>Venous thromboembolism</td>
</tr>
</tbody>
</table>

### Hepatitis a vaccine

<table>
<thead>
<tr>
<th><strong>Recommendations for some high-risk populations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
</tbody>
</table>

### Hepatitis b vaccine

<table>
<thead>
<tr>
<th><strong>Recommendations for all immunization programmes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
</tbody>
</table>

### Homatropine

<table>
<thead>
<tr>
<th><strong>Ophthalmological preparations &gt; Mydriatics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 2% (hydrobromide)</td>
</tr>
</tbody>
</table>

### Human papilloma virus (HPV) vaccine

<table>
<thead>
<tr>
<th><strong>Recommendations for all immunization programmes</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
</tbody>
</table>

### Hydralazine

<table>
<thead>
<tr>
<th><strong>Antihypertensive medicines</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 20 mg in ampoule powder for injection (hydrochloride)</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg tablet; 25 mg tablet (hydrochloride)</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)</td>
</tr>
</tbody>
</table>

### Therapeutic equivalent to atropine for

<table>
<thead>
<tr>
<th>Anterior uveitis</th>
</tr>
</thead>
</table>

### Need for immunization against certain single viral diseases

<table>
<thead>
<tr>
<th>Human papilloma virus (HPV) vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
</tbody>
</table>
### Hydrochlorothiazide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihypertensive medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per 5 mL</td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg; 12.5 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Medicines used in heart failure</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per 5 mL</td>
<td>Heart failure</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td>Oedema</td>
</tr>
</tbody>
</table>

### Hydrocortisone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormones and antihormones</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 100 mg in vial (as sodium succinate)</td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td></td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Burkitt lymphoma including Burkitt leukaemia</td>
</tr>
<tr>
<td><strong>Adrenal hormones and synthetic substitutes</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg; 10 mg; 20 mg</td>
<td>Adrenocortical insufficiency</td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Anti-inflammatory agents</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Ointment: 1% (acetate)</td>
<td>Scleritis</td>
</tr>
<tr>
<td></td>
<td>Anterior uveitis</td>
</tr>
<tr>
<td><strong>Antiallergics and medicines used in anaphylaxis</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 100 mg in vial powder for injection (as sodium succinate)</td>
<td>Anaphylaxis</td>
</tr>
<tr>
<td><strong>Anti-inflammatory medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Suppository: 25 mg (acetate)</td>
<td>Crohn disease site</td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Retention enema: 100 mg per 60 mL</td>
<td>Ulcerative colitis</td>
</tr>
<tr>
<td><strong>Dermatological medicines &gt; Anti-inflammatory and antipruritic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 1% (acetate)</td>
<td>Dermatitis or eczema</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Ointment: 1% (acetate)</td>
<td>Pruritus due to skin disorder</td>
</tr>
<tr>
<td></td>
<td>Psoriasis of unspecified type</td>
</tr>
<tr>
<td></td>
<td>Lichen planus</td>
</tr>
<tr>
<td><strong>Hydromorphone</strong></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Opioid analgesics</td>
<td>Therapeutic equivalent to morphine for Pain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hydroxocobalamin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antianaemia medicines</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hydroxycarbamide (hydroxyurea)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Other medicines for haemoglobinopathies</td>
</tr>
<tr>
<td>Cytotoxic medicines</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hydroxychloroquine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antimalarial medicines &gt; For chemoprevention</td>
</tr>
<tr>
<td>Disease-modifying anti-rheumatic drugs (DMARDs)</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg (as sulfate)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hyoscine butylbromide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 20 mg per mL injection</td>
</tr>
<tr>
<td>Hyoscine hydrobromide</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Transdermal patch: 1 mg per 72 hours transdermal patch</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 400 µg per mL injection; 600 µg per mL injection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hypochlorous acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiseptics</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ibrutinib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
</tr>
<tr>
<td>Oral &gt; Solid: 140 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ibuprofen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimigraine medicines &gt; For treatment of acute attack</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 400 mg</td>
</tr>
<tr>
<td>Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 200 mg per 5 mL</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 400 mg; 600 mg</td>
</tr>
<tr>
<td>Medicines administered to the neonate [c]</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5 mg per mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Idoxuridine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmological preparations &gt; Anti-infective agents</td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.1%</td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Ointment: 0.2%</td>
</tr>
</tbody>
</table>
### Ifosfamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 mg in vial powder for injection; 1 g in vial powder for injection</td>
<td>Other specified malignant neoplasms of the ovary</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 g in vial powder for injection; 2 g in vial powder for injection</td>
<td>Germ cell tumour of testis</td>
</tr>
<tr>
<td></td>
<td>Ewing sarcoma of bone and articular cartilage of unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Osteosarcoma of bone and articular cartilage of unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Rhabdomyosarcoma primary site</td>
</tr>
<tr>
<td></td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Burkitt lymphoma including Burkitt leukaemia</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of kidney, except renal pelvis</td>
</tr>
</tbody>
</table>

### Imatinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted therapies</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 400 mg</td>
<td>B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2): BCR-ABL1</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal stromal tumour of unspecified gastrointestinal sites</td>
</tr>
<tr>
<td></td>
<td>Chronic myeloid leukaemia, not elsewhere classified</td>
</tr>
</tbody>
</table>
## Imipenem + cilastatin

**Watch group antibiotics**
- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

### Second choice
- Therapeutic equivalent to meropenem for Neutropenia (high-risk)
- Therapeutic equivalent to meropenem for Peritoneal abscess (severe)
- Therapeutic equivalent to meropenem for Peritonitis (severe)

### Other indications
- Pseudomonas aeruginosa resistant to other antibiotic
- Antibiotic resistant Acinetobacter baumannii
- Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis

### Antituberculosis medicines

## Indapamide

**Section**
- Antihypertensive medicines
- Medicines used in heart failure

### Indications
- Therapeutic equivalent to hydrochlorothiazide for Essential hypertension
- Therapeutic equivalent to hydrochlorothiazide for Heart failure

## Indinavir

**Section**
- Antiretrovirals > Protease inhibitors
  - Oral > Solid: 400 mg (as sulfate)

### Indications
- Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Indometacin

**Section**
- Medicines administered to the neonate [c]

### Indications
- Therapeutic equivalent to ibuprofen for Patent arterial duct
### Influenza vaccine (seasonal)

#### Recommendations for immunization programmes with certain characteristics

All vaccines should comply with the WHO requirements for biological substances.

#### Indications

- Need for immunization against influenza

### Insulin

#### Insulins

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus</td>
</tr>
</tbody>
</table>

**Parenteral > General injections > SC:**

- 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble)

### Insulin analogues

#### Insulins

- Type 1 diabetes mellitus
- Type 2 diabetes mellitus

#### Not specified

### Insulin degludec

#### Insulins

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus</td>
</tr>
</tbody>
</table>

**Parenteral > General injections > SC:**

- 100 units per mL
<table>
<thead>
<tr>
<th>Insulin detemir</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Insulins</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Insulin glargine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Insulins</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 100 units per mL</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
</tr>
<tr>
<td>Parenteral solution</td>
</tr>
<tr>
<td>Parenteral solution</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intermediate-acting insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Insulins</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin</td>
</tr>
<tr>
<td>Parenteral solution</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intraperitoneal dialysis solution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Peritoneal dialysis solution</td>
</tr>
<tr>
<td>Parenteral solution</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
### Iodine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamins and minerals</td>
<td>Iodine deficiency</td>
</tr>
</tbody>
</table>

**Parenteral > General injections > IM:** 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule

**Oral > Liquid:** 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle

**Oral > Solid:** 190 mg

### Iohexol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic agents &gt; Radiocontrast media</td>
<td>X-ray contrast media, iohinated</td>
</tr>
</tbody>
</table>

**Parenteral > General injections > unspecified:** 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

### Ipecacuanha

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Non-specific</td>
<td>Unspecified injury, poisoning or certain other consequences of external causes</td>
</tr>
</tbody>
</table>

**Oral > Liquid:** 0.14% ipecacuanha alkaloids calculated as emetine

### Ipratropium bromide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiasthmatic and medicines for chronic obstructive pulmonary disease</td>
<td>Asthma, Chronic obstructive pulmonary disease</td>
</tr>
</tbody>
</table>

**Respiratory > Inhalation > aerosol:** 20 µg per dose

### Irinotecan

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td>Malignant neoplasm metastasis in large intestine, Malignant neoplasms of kidney, except renal pelvis, Rhabdomyosarcoma primary site</td>
</tr>
</tbody>
</table>

**Parenteral > General injections > IV:** 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
### Isoflurane

<table>
<thead>
<tr>
<th>General anaesthetics and oxygen &gt; Inhalational medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory &gt; Inhalation &gt; liquid:</td>
<td>Anaesthetics and therapeutic gases</td>
</tr>
</tbody>
</table>

### Isoniazid

<table>
<thead>
<tr>
<th>Antituberculosis medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Liquid: 50 mg per 5 mL</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet</td>
<td>Other specified tuberculosis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg per mL</td>
<td></td>
</tr>
</tbody>
</table>

### Isoniazid + pyrazinamide + rifampicin

<table>
<thead>
<tr>
<th>Antituberculosis medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)</td>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>

### Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

<table>
<thead>
<tr>
<th>Medicines for prevention of HIV-related opportunistic infections</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)</td>
<td>Other specified prophylactic measures</td>
</tr>
</tbody>
</table>

### Isoniazid + rifampicin

<table>
<thead>
<tr>
<th>Antituberculosis medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet</td>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>

### Isoniazid + rifapentine

<table>
<thead>
<tr>
<th>Antituberculosis medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 300 mg + 300 mg tablet (scored)</td>
<td>Latent tuberculosis</td>
</tr>
</tbody>
</table>
### Isoprenaline

#### Antiarrhythmic medicines
- **Oral > Solid**: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)
- **Parenteral > General injections > IV**: 20 µg per mL in ampoule (hydrochloride)

**Indications**
- Cardiogenic shock
- Bradycardia

### Isosorbide dinitrate

#### Antianginal medicines
- **Oral > Solid**: 5 mg sublingual tablet

**Indications**
- Angina pectoris

### Itraconazole

#### Antifungal medicines
- **Oral > Liquid**: 10 mg per mL
- **Oral > Solid**: 100 mg

**Indications**
- Chronic pulmonary aspergillosis
- Chromoblastomycosis
- Histoplasmosis
- Talaromycosis
- Sporotrichosis
- Paracoccidioidomycosis

### Ivermectin

#### Intestinal anthelmintics
- **Oral > Solid**: 3 mg tablet (scored)

**Indications**
- Strongyloidiasis
- Ascariasis
- Trichuriasis
- Hookworm diseases
- Ancylostomiasis

#### Antifilarials
- **Oral > Solid**: 3 mg tablet (scored)

**Indications**
- Onchocerciasis
- Lymphatic filariasis

#### Medicines for ectoparasitic infections
- **Oral > Solid**: 3 mg tablet (scored)

**Indications**
- Scabies
### Kanamycin

**Ophthalmological preparations > Anti-infective agents**
- Therapeutic equivalent to gentamicin for:
  - **Other specified conjunctivitis**
  - **Infectious blepharitis**

### Kanamycin (injection)

**Antituberculosis medicines**
- **Parenteral > General injections > IV**:
  - 1000 mg powder for injection (vial)
  - **Multi-drug resistant Mycobacterium tuberculosis**

### Ketamine

**General anaesthetics and oxygen > Injectable medicines**
- **Parenteral > General injections > unspecified**:
  - 50 mg per mL in 10 mL vial (as hydrochloride)
  - **Anaesthetics and therapeutic gases**

### Lactulose

**Medicines for other common symptoms in palliative care**
- **Oral > Liquid**:
  - 3.1 to 3.7 g per 5 mL oral liquid
  - **Palliative care**

### Lamivudine

**Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors**
- **Oral > Liquid**:
  - 50 mg per 5 mL
  - **Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified**
- **Oral > Solid**:
  - 150 mg tablet

### Lamivudine + nevirapine + zidovudine

**Fixed-dose combinations of antiretrovirals**
- **Oral > Solid**:
  - 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
  - **Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified**
<table>
<thead>
<tr>
<th><strong>Lamivudine + tenofovir</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td>Therapeutic equivalent to emtricitabine + tenofovir for:</td>
</tr>
<tr>
<td></td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to emtricitabine + tenofovir for:</td>
</tr>
<tr>
<td></td>
<td>Contact with or exposure to human immunodeficiency virus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Lamivudine + zidovudine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Fixed-dose combinations of antiretrovirals</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Lamotrigine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td>Epidy or seizures</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Latanoprost</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Miotics and antiglaucoma medicines</strong></td>
<td>Primary open-angle glaucoma</td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 50 µg per mL eye drops</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ledipasvir + sofosbuvir</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Medicines for hepatitis C &gt; Non-pangenotypic direct-acting antiviral combinations</strong></td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Oral &gt; Solid: 90 mg + 400 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Lenalidomide</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
<td>Plasma cell myeloma</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Leuprolelin</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Hormones and antihormones</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe</td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of prostate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Levamisole</strong></th>
<th><strong>Indications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intestinal anthelminthics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg tablet; 150 mg tablet (as hydrochloride)</td>
<td>Ascariasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Levodopa</strong></th>
<th><strong>Indications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg</td>
<td>Parkinson disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Levodopa + benserazide</strong></th>
<th><strong>Indications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for parkinsonism</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to levodopa + carbidopa for Parkinson disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Levodopa + carbidopa</strong></th>
<th><strong>Indications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for parkinsonism</strong></td>
<td></td>
</tr>
<tr>
<td>Parkinson disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Levofloxacin</strong></th>
<th><strong>Indications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)</td>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
</tbody>
</table>
## Levonorgestrel

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral hormonal contraceptives</strong>&lt;br&gt;Oral &gt; Solid: 750 µg [2]; 1.5 mg [1]&lt;br&gt;Oral &gt; Solid: 30 µg</td>
<td>Contact with health services for postcoital contraception&lt;br&gt;Contact with health services for contraceptive management</td>
</tr>
<tr>
<td><strong>Intrauterine devices</strong>&lt;br&gt;Intrauterine system with reservoir containing 52 mg of levonorgestrel.</td>
<td>Contact with health services for insertion of contraceptive device</td>
</tr>
</tbody>
</table>

## Levonorgestrel-releasing implant

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Implantable contraceptives</strong>&lt;br&gt;Implant &gt; Subdermal: 75 mg per rod (two-rods)</td>
<td>Contact with health services for insertion of contraceptive device</td>
</tr>
</tbody>
</table>

## Levothyroxine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thyroid hormones and antithyroid medicines</strong>&lt;br&gt;Oral &gt; Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)</td>
<td>Hypothyroidism</td>
</tr>
</tbody>
</table>

## Lidocaine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiarrhythmic medicines</strong>&lt;br&gt;Parenteral &gt; General injections &gt; IV: 20 mg per mL in 5 mL ampoule (hydrochloride)</td>
<td>Ventricular tachyarrhythmia</td>
</tr>
<tr>
<td><strong>Local anaesthetics</strong>&lt;br&gt;Parenteral &gt; Locoregional injections &gt; Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution&lt;br&gt;Parenteral &gt; Locoregional injections &gt; Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)&lt;br&gt;Local &gt; Topical &gt; unspecified: 2 to 4% (hydrochloride)</td>
<td>Local anaesthetics</td>
</tr>
</tbody>
</table>
### Lidocaine + epinephrine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Local anaesthetics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; Locoregional</td>
<td>Local anaesthetics</td>
</tr>
<tr>
<td>injections &gt; Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Dental &gt; Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine</td>
<td></td>
</tr>
</tbody>
</table>

### Lindane

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatological medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Scabicides and pediculicides</td>
<td>Scabies</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 1%</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Lotion: 1%</td>
<td></td>
</tr>
</tbody>
</table>

### Linezolid

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td>Other specified bacterial diseases</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 2 mg per mL in 300 mL bag</td>
<td>Methicillin resistant Staphylococcus aureus</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 100 mg per 5 mL powder for oral liquid</td>
<td>Vancomycin resistant Staphylococcus aureus</td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg tablet; 600 mg tablet</td>
<td>Vancomycin resistant Enterococcus</td>
</tr>
</tbody>
</table>

### Lisinopril + amlodipine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihypertensive medicines</strong></td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Lisinopril + hydrochlorothiazide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihypertensive medicines</strong></td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Lithium carbonate</strong></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Medicines for bipolar disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td></td>
</tr>
<tr>
<td>Bipolar or related disorders</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Long-acting insulin analogues</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insulins</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Loperamide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for other common symptoms in palliative care</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 2 mg solid oral dosage form</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Palliative care</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Lopinavir + ritonavir</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiretrovirals &gt; Protease inhibitors</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Loratadine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiallergics and medicines used in anaphylaxis</strong></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 1 mg per mL</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Allergic or hypersensitivity conditions of unspecified type</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Lorazepam</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Status epilepticus</td>
</tr>
<tr>
<td>Section</td>
</tr>
<tr>
<td>----------------------------------------------</td>
</tr>
<tr>
<td><strong>Losartan</strong></td>
</tr>
<tr>
<td><strong>Antihypertensive medicines</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet</td>
</tr>
<tr>
<td><strong>Medicines used in heart failure</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet</td>
</tr>
<tr>
<td><strong>Lovastatin</strong></td>
</tr>
<tr>
<td><strong>Lipid-lowering agents</strong></td>
</tr>
<tr>
<td>Therapeutic equivalent to simvastatin for</td>
</tr>
<tr>
<td>Mixed hyperlipidaemia</td>
</tr>
<tr>
<td>Therapeutic equivalent to simvastatin for</td>
</tr>
<tr>
<td>Coronary atherosclerosis</td>
</tr>
<tr>
<td><strong>Lugol’s solution</strong></td>
</tr>
<tr>
<td><strong>Thyroid hormones and antithyroid medicines</strong></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 13% w/v (about 130 mg/mL total iodine)</td>
</tr>
<tr>
<td><strong>Magnesium sulfate</strong></td>
</tr>
<tr>
<td><strong>Antiseizure medicines</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)</td>
</tr>
<tr>
<td><strong>Mannitol</strong></td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10% solution; 20% solution</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
### Measles vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendations for all immunization programmes</strong>&lt;br&gt;All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against measles alone</td>
</tr>
</tbody>
</table>

### Mebendazole

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cysticidal medicines</strong>&lt;br&gt;Oral &gt; Solid: 500 mg tablet (chewable)</td>
<td>Other specified echinococciosis</td>
</tr>
<tr>
<td><strong>Intestinal anthelmintics</strong>&lt;br&gt;Oral &gt; Solid &gt; tablet: 100 mg (chewable); 500 mg (chewable)</td>
<td>Ascariasis&lt;br&gt;Enterobiasis&lt;br&gt;Trichuriasis&lt;br&gt;Hookworm diseases</td>
</tr>
</tbody>
</table>

### Medroxyprogesterone acetate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Injectable hormonal contraceptives</strong>&lt;br&gt;Parenteral &gt; General injections &gt; IM: 150 mg per mL in 1 mL vial&lt;br&gt;Parenteral &gt; General injections &gt; SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system</td>
<td>Contact with health services for reasons associated with reproduction&lt;br&gt;Excessive menstruation with irregular cycle</td>
</tr>
<tr>
<td><strong>Progestogens</strong>&lt;br&gt;Oral &gt; Solid: 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Mefloquine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimalarial medicines &gt; For curative treatment</strong>&lt;br&gt;Oral &gt; Solid: 250 mg tablet (hydrochloride)</td>
<td>Malaria due to Plasmodium falciparum&lt;br&gt;Malaria due to Plasmodium vivax</td>
</tr>
<tr>
<td><strong>Antimalarial medicines &gt; For chemoprevention</strong>&lt;br&gt;Oral &gt; Solid: 250 mg tablet (hydrochloride)</td>
<td>Malaria due to Plasmodium falciparum</td>
</tr>
<tr>
<td><strong>Meglumine antimoniate</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Antileishmaniasis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony</td>
<td>Visceral leishmaniasis</td>
</tr>
<tr>
<td></td>
<td>Mucocutaneous leishmaniasis</td>
</tr>
<tr>
<td></td>
<td>Cutaneous leishmaniasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Meglumine iotroxate</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Diagnostic agents &gt; Radiocontrast media</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL</td>
<td>X-ray contrast media, iodinated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Melarsoprol</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Medicines for the treatment of 2nd stage African trypanosomiasis</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)</td>
<td>African trypanosomiasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Melphalan</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg in vial powder for injection</td>
<td>Plasma cell myeloma</td>
</tr>
<tr>
<td>Oral &gt; Solid: 2 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Meningococcal meningitis vaccine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Recommendations for some high-risk populations</strong></td>
<td></td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against single bacterial diseases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Mercaptopurine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg tablet</td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td></td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td></td>
<td>Acute myeloid leukaemia with recurrent genetic abnormalities</td>
</tr>
</tbody>
</table>
### Meropenem

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Watch group antibiotics</strong></td>
<td>Second choice</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection</td>
<td>Neutropenia (high-risk)</td>
</tr>
<tr>
<td></td>
<td>Peritoneal abscess (severe)</td>
</tr>
<tr>
<td></td>
<td>Peritonitis (severe)</td>
</tr>
<tr>
<td></td>
<td>Neonatal meningitis</td>
</tr>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection</td>
<td></td>
</tr>
</tbody>
</table>

### Meropenem + vaborbactam

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td>Carbapenem-resistant Pseudomonas aeruginosa</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 g in vial + 1 g in vial powder for injection</td>
<td>Carbapenem resistant Enterobacterales</td>
</tr>
<tr>
<td></td>
<td>Carbapenem resistant Acinetobacter baumannii</td>
</tr>
</tbody>
</table>

### Mesalazine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-inflammatory medicines</strong></td>
<td>Therapeutic equivalent to sulfasalazine for</td>
</tr>
<tr>
<td></td>
<td>Crohn disease site</td>
</tr>
<tr>
<td></td>
<td>Ulcerative colitis</td>
</tr>
</tbody>
</table>
### Mesna

**Supportive medicines**
- **Parenteral** > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- **Oral** > Solid: 400 mg; 600 mg

<table>
<thead>
<tr>
<th>Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteosarcoma of bone and articular cartilage of other specified sites</td>
<td></td>
</tr>
<tr>
<td>Other specified malignant neoplasms of the ovary</td>
<td></td>
</tr>
<tr>
<td>Germ cell tumour of testis</td>
<td></td>
</tr>
<tr>
<td>Ewing sarcoma of bone and articular cartilage of unspecified sites</td>
<td></td>
</tr>
<tr>
<td>Rhabdomyosarcoma primary site</td>
<td></td>
</tr>
<tr>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
<td></td>
</tr>
<tr>
<td>Burkitt lymphoma including Burkitt leukaemia</td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms of kidney, except renal pelvis</td>
<td></td>
</tr>
</tbody>
</table>

### Metformin

**Oral hypoglycaemic agents**
- **Oral** > Solid: 500 mg (hydrochloride)

<table>
<thead>
<tr>
<th>Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 diabetes mellitus</td>
<td></td>
</tr>
</tbody>
</table>

### Methadone

**Medicines for disorders due to psychoactive substance use**
- **Oral** > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

**Opioid analgesics**
- **Oral** > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
- **Oral** > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

<table>
<thead>
<tr>
<th>Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid dependence</td>
<td></td>
</tr>
<tr>
<td>Chronic cancer pain</td>
<td></td>
</tr>
</tbody>
</table>

### Methimazole

**Thyroid hormones and antithyroid medicines**
- **Oral** > Solid: 5 mg; 10 mg; 20 mg

<table>
<thead>
<tr>
<th>Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyrotoxicosis</td>
<td></td>
</tr>
</tbody>
</table>
### Methionine

**Antidotes and other substances used in poisonings > Specific**

**Oral > Solid: 250 mg (DL)**

*Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs*

### Methotrexate

**Cytotoxic medicines**

**Parenteral > General injections > IV: 50 mg in vial (as sodium salt)**

**Oral > Solid: 2.5 mg (as sodium salt)**

*Unspecified malignant neoplasms of ill-defined or unspecified sites*

*Lymphoid leukaemia, not elsewhere classified*

*Acute myeloid leukaemia with recurrent genetic abnormalities*

*Burkitt lymphoma including Burkitt leukaemia*

*Malignant neoplasms of breast*

*Malignant trophoblastic neoplasms of placenta*

*Osteosarcoma of bone and articular cartilage of unspecified sites*

**Medicines for juvenile joint diseases**

**Oral > Solid: 2.5 mg (as sodium salt)**

*Juvenile idiopathic arthritis*

**Disease-modifying anti-rheumatic drugs (DMARDs)**

**Oral > Solid: 2.5 mg (as sodium salt)**

*Rheumatoid arthritis, serology unspecified*

### Methoxy polyethylene glycol-epoetin beta

**Antianaemia medicines**

*Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease*

### Methyldopa

**Antihypertensive medicines**

**Oral > Solid: 250 mg**

*Essential hypertension*

*Gestational hypertension*
### Methylergometrine

#### Uterotonics

Therapeutic equivalent to ergometrine for

- Postpartum haemorrhage

### Methylphenidate

#### Medicines for mental and behavioural disorders

Attention deficit hyperactivity disorder

Multiple formulations and strengths.

### Methylprednisolone

#### Hormones and antihormones

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

### Methylthioninium chloride

#### Antidotes and other substances used in poisonings > Specific

Acquired methaemoglobinaemia

Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

### Metoclopramide

#### Medicines for other common symptoms in palliative care

Palliative care

Oral > Liquid: 5 mg per 5 mL

Oral > Solid: 10 mg (hydrochloride)

Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

#### Antiemetic medicines

Nausea or vomiting

Oral > Liquid: 5 mg per 5 mL

Oral > Solid: 10 mg (hydrochloride)

Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antianginal medicines</strong></td>
<td>Therapeutic equivalent to bisoprolol for</td>
</tr>
<tr>
<td></td>
<td>Angina pectoris</td>
</tr>
<tr>
<td><strong>Medicines used in heart failure</strong></td>
<td>Therapeutic equivalent to bisoprolol for</td>
</tr>
<tr>
<td></td>
<td>Heart failure</td>
</tr>
<tr>
<td><strong>Antiarrhythmic medicines</strong></td>
<td>Therapeutic equivalent to bisoprolol for</td>
</tr>
<tr>
<td></td>
<td>Cardiac arrhythmia</td>
</tr>
<tr>
<td><strong>Antihypertensive medicines</strong></td>
<td>Therapeutic equivalent to bisoprolol for</td>
</tr>
<tr>
<td></td>
<td>Essential hypertension</td>
</tr>
</tbody>
</table>
### Metronidazole

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access group antibiotics</strong></td>
<td><strong>First choice</strong></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 200 mg per 5 mL (as benzoate)</td>
<td>Trichomoniasis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 to 500 mg tablet</td>
<td>Intestinal infections due to <em>Clostridioides difficile</em></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 500 mg per 100 mL in vial</td>
<td>co-prescribed with <em>cefa</em>zolin</td>
</tr>
<tr>
<td>Injection</td>
<td>Other specified prophylactic measures</td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Suppository: 500 mg suppository; 1 g suppository</td>
<td></td>
</tr>
<tr>
<td><strong>Oral &gt; Liquid: 200 mg per 5 mL (as benzoate)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Oral &gt; Solid: 200 to 500 mg tablet</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; unspecified: 500 mg in 100 mL vial</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Local &gt; Rectal &gt; Suppository: 500 mg suppository; 1 g suppository</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Antiamoebic and antiigiardiasis medicines

| Oral > Liquid: 200 mg per 5 mL (as benzoate) | **Second choice** |
| Oral > Solid: 200 to 500 mg tablet | co-prescribed with *cipro*floxacin |
| Parenteral > General injections > unspecified: 500 mg in 100 mL vial | **Peritoneal abscess (mild-moderate)** |

### Other indications

<p>| <strong>Bacterial infection of unspecified site</strong> | <strong>Peritonitis (mild-moderate)</strong> |
| <strong>Amoebiasis</strong> | <strong>Peritonitis (severe)</strong> |</p>
<table>
<thead>
<tr>
<th>Medication</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Micafungin</strong></td>
<td></td>
</tr>
<tr>
<td>Antifungal</td>
<td>Systemic or invasive candidosis</td>
</tr>
<tr>
<td>medicines</td>
<td></td>
</tr>
<tr>
<td>Parenteral</td>
<td>IV: 50 mg in vial (as sodium) powder for injection;</td>
</tr>
<tr>
<td></td>
<td>100 mg in vial (as sodium) powder for injection</td>
</tr>
<tr>
<td><strong>Miconazole</strong></td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>Fungal infection of the skin</td>
</tr>
<tr>
<td>medicines</td>
<td></td>
</tr>
<tr>
<td>Local</td>
<td>Local &gt; Topical &gt; Cream: 2% (nitrate)</td>
</tr>
<tr>
<td></td>
<td>Local &gt; Topical &gt; Ointment: 2% (nitrate)</td>
</tr>
<tr>
<td><strong>Midazolam</strong></td>
<td></td>
</tr>
<tr>
<td>Antiseizure</td>
<td>Status epilepticus</td>
</tr>
<tr>
<td>medicines</td>
<td>Therapeutic equivalent to lorazepam for</td>
</tr>
<tr>
<td>Parenteral</td>
<td>Status epilepticus</td>
</tr>
<tr>
<td></td>
<td>Parenteral &gt; General injections &gt; unspecified: 1 mg</td>
</tr>
<tr>
<td></td>
<td>per mL in ampoule (for buccal administration); 10</td>
</tr>
<tr>
<td></td>
<td>mg per mL in ampoule (for buccal administration)</td>
</tr>
<tr>
<td>Local</td>
<td>Local &gt; Buccal &gt; Solution: 5 mg per mL solution for</td>
</tr>
<tr>
<td></td>
<td>oromucosal administration; 10 mg per mL solution for</td>
</tr>
<tr>
<td></td>
<td>oromucosal administration</td>
</tr>
<tr>
<td>Medicines</td>
<td></td>
</tr>
<tr>
<td>for other</td>
<td></td>
</tr>
<tr>
<td>common symptoms</td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>Oral &gt; Liquid: 2 mg per mL oral liquid</td>
</tr>
<tr>
<td></td>
<td>Oral &gt; Solid: 7.5 mg solid oral dosage form; 15</td>
</tr>
<tr>
<td></td>
<td>mg solid oral dosage form</td>
</tr>
<tr>
<td>Parenteral</td>
<td>Parenteral &gt; General injections &gt; unspecified: 1 mg</td>
</tr>
<tr>
<td></td>
<td>per mL injection; 5 mg per mL injection</td>
</tr>
<tr>
<td>Preoperative</td>
<td></td>
</tr>
<tr>
<td>medication and</td>
<td></td>
</tr>
<tr>
<td>sedation for</td>
<td></td>
</tr>
<tr>
<td>short-term</td>
<td></td>
</tr>
<tr>
<td>procedures</td>
<td></td>
</tr>
<tr>
<td>Parenteral</td>
<td>Parenteral &gt; General injections &gt; IV: 1 mg per mL</td>
</tr>
<tr>
<td>Oral</td>
<td>Oral &gt; Liquid: 2 mg per mL</td>
</tr>
<tr>
<td></td>
<td>Oral &gt; Solid: 15 mg tablet; 7.5 mg tablet</td>
</tr>
<tr>
<td><strong>Mifepristone</strong></td>
<td></td>
</tr>
<tr>
<td>- misoprostol</td>
<td></td>
</tr>
<tr>
<td>Uterotonics</td>
<td>Induced abortion</td>
</tr>
<tr>
<td>Oral</td>
<td>Oral &gt; Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg</td>
</tr>
<tr>
<td></td>
<td>[4] in co-package</td>
</tr>
</tbody>
</table>
### Miltefosine

**Section**

**Antileishmaniasis medicines**

| Oral > Solid: 10 mg; 50 mg |

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral leishmaniasis</td>
</tr>
<tr>
<td>Mucocutaneous leishmaniasis</td>
</tr>
<tr>
<td>Cutaneous leishmaniasis</td>
</tr>
</tbody>
</table>

### Misoprostol

**Section**

**Uterotonics**

<table>
<thead>
<tr>
<th>Oral &gt; Solid: 200 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local &gt; Vaginal &gt; tablet: 25 µg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous abortion, incomplete, without complication</td>
</tr>
<tr>
<td>Unspecified obstetric condition</td>
</tr>
<tr>
<td>Postpartum haemorrhage</td>
</tr>
</tbody>
</table>

### Mometasone

**Section**

**Antiasthmatic and medicines for chronic obstructive pulmonary disease**

| Therapeutic equivalent to budesonide for Asthma |

### Mometasone + formoterol

**Section**

**Antiasthmatic and medicines for chronic obstructive pulmonary disease**

| Therapeutic equivalent to budesonide + formoterol for Asthma |


### Morphine

<table>
<thead>
<tr>
<th>Preoperative medication and sedation for short-term procedures</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)</td>
<td>Opioids or related analgesics and agents affecting opioid receptors</td>
</tr>
<tr>
<td><strong>Opioid analgesics</strong></td>
<td>Pain</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)</td>
<td></td>
</tr>
</tbody>
</table>

### Moxifloxacin

<table>
<thead>
<tr>
<th>Antituberculosis medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 400 mg tablet; 100 mg tablet (dispersible)</td>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg tablet</td>
<td>Tuberculosis</td>
</tr>
</tbody>
</table>

### Multiple micronutrient powder

<table>
<thead>
<tr>
<th>Vitamins and minerals</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Other:</td>
<td>Iron deficiency anaemia</td>
</tr>
<tr>
<td>Multiple micronutrient supplement</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td><strong>Other medicines administered to the mother</strong></td>
<td>Maternal care for other specified conditions predominantly related to pregnancy</td>
</tr>
<tr>
<td>Tablet containing:</td>
<td></td>
</tr>
<tr>
<td>Vit A: 800 mcg retinol activity equivalent</td>
<td></td>
</tr>
<tr>
<td>Vit C: 70 mg</td>
<td></td>
</tr>
<tr>
<td>Vit D: 5 mcg (200 IU)</td>
<td></td>
</tr>
<tr>
<td>Vit E: 10 mg alpha tocopherol equivalent</td>
<td></td>
</tr>
<tr>
<td>Vit B1: 1.4 mg</td>
<td></td>
</tr>
<tr>
<td>Vit B2: 1.4 mg</td>
<td></td>
</tr>
<tr>
<td>Vit B3: 18 mg niacin equivalent</td>
<td></td>
</tr>
<tr>
<td>Vit B6: 1.9 mg</td>
<td></td>
</tr>
<tr>
<td>Folic acid: 400 mcg</td>
<td></td>
</tr>
<tr>
<td>Vit B12: 2.6 mcg</td>
<td></td>
</tr>
<tr>
<td>Iron: 30 mg</td>
<td></td>
</tr>
<tr>
<td>Iodine: 150 mcg</td>
<td></td>
</tr>
<tr>
<td>Zinc: 15 mg</td>
<td></td>
</tr>
<tr>
<td>Selenium: 65 mcg</td>
<td></td>
</tr>
<tr>
<td>Copper: 2 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mumps vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td><strong>Recommendations for immunization programmes with certain characteristics</strong></td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mupirocin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td><strong>Dermatological medicines &gt; Anti-infective medicines</strong></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 2% (as mupirocin calcium)</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Ointment: 2%</td>
</tr>
<tr>
<td>Section</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td><strong>Nadroparin</strong></td>
</tr>
<tr>
<td>Therapeutic equivalent to enoxaparin for</td>
</tr>
<tr>
<td>- Acute ischaemic heart disease</td>
</tr>
<tr>
<td>- Venous thromboembolism</td>
</tr>
<tr>
<td><strong>Nalidixic acid</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg; 500 mg</td>
</tr>
<tr>
<td>Shigella resistant to unspecified antibiotic</td>
</tr>
<tr>
<td><strong>Naloxone</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)</td>
</tr>
<tr>
<td>Unintentional exposure to or harmful effects of opioids or related analgesics</td>
</tr>
<tr>
<td><strong>Natamycin</strong></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Suspension: 5% eye drops</td>
</tr>
<tr>
<td>Infectious keratitis</td>
</tr>
<tr>
<td><strong>Nelfinavir</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg (as mesilate)</td>
</tr>
<tr>
<td>Oral &gt; Other: 50 mg per g oral powder</td>
</tr>
<tr>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td><strong>Neostigmine</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 15 mg (neostigmine bromide)</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)</td>
</tr>
<tr>
<td>Myasthenia gravis</td>
</tr>
<tr>
<td>Anticholinesterase reversible</td>
</tr>
</tbody>
</table>
### Netilmicin

**Section**

**Ophthalmological preparations > Anti-infective agents**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Therapeutic equivalent to gentamicin for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other specified conjunctivitis</td>
<td></td>
</tr>
<tr>
<td>Infectious blepharitis</td>
<td></td>
</tr>
</tbody>
</table>

### Nevirapine

**Section**

**Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</th>
</tr>
</thead>
</table>

### Niclosamide

**Section**

**Intestinal anthelmintics**

<table>
<thead>
<tr>
<th>Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hymenolepiasis</td>
<td></td>
</tr>
<tr>
<td>Diphyllobothriasis</td>
<td></td>
</tr>
<tr>
<td>Taeniasis due to Taenia saginata</td>
<td></td>
</tr>
<tr>
<td>Taeniasis due to Taenia solium</td>
<td></td>
</tr>
</tbody>
</table>

### Nicotinamide

**Section**

**Vitamins and minerals**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Pellagra</th>
</tr>
</thead>
</table>

### Nicotine replacement therapy

**Section**

**Medicines for disorders due to psychoactive substance use**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Nicotine dependence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Other: 2 mg chewing gum; 4 mg chewing gum</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour</td>
<td></td>
</tr>
<tr>
<td><strong>Nifedipine</strong></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Antioxytocics (tocolytics)</td>
<td>Preterm labour without delivery</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg (immediate-release)</td>
<td></td>
</tr>
<tr>
<td>Antianginal medicines</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg</td>
<td></td>
</tr>
<tr>
<td>Antihypertensive medicines</td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet; sustained-release formulations</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nifurtimox</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Medicines for the treatment of 2nd stage African trypanosomiasis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 120 mg</td>
</tr>
<tr>
<td>American trypanosomiasis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nilotinib</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Targeted therapies</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg capsule; 200 mg capsule</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nilutamide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Hormones and antihormones</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nitrofurantoin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Access group antibiotics</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 25 mg per 5 mL oral liquid</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg tablet</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nitrous oxide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>General anaesthetics and oxygen &gt; Inhalational medicines</td>
</tr>
<tr>
<td>Respiratory &gt; Inhalation:</td>
</tr>
</tbody>
</table>
### Nivolumab

**Immunomodulators**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL concentrate solution for infusion</td>
<td>Other specified malignant neoplasms of bronchus or lung; Melanoma of skin</td>
</tr>
</tbody>
</table>

### Norethisterone

**Oral hormonal contraceptives**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 350 µg</td>
<td>Contact with health services for contraceptive management</td>
</tr>
</tbody>
</table>

**Progestogens**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 5 mg</td>
<td>Excessive menstruation with irregular cycle; Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle</td>
</tr>
</tbody>
</table>

### Norethisterone enantate

**Injectable hormonal contraceptives**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 200 mg per mL in 1 mL ampoule oily solution</td>
<td>Contact with health services for reasons associated with reproduction</td>
</tr>
</tbody>
</table>

### Normal immunoglobulin

**Human immunoglobulins**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5% protein solution; 10% protein solution</td>
<td>Primary immunodeficiencies</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 16% protein solution</td>
<td>Mucocutaneous lymph node syndrome</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 15% protein solution; 16% protein solution</td>
<td></td>
</tr>
</tbody>
</table>

### Nystatin

**Antifungal medicines**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Liquid: 100000 IU per mL; 50 mg per 5 mL</td>
<td>Candidosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Other: 100000 IU pessary</td>
<td></td>
</tr>
<tr>
<td><strong>Ocrelizumab</strong></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Immunomodulators for non-malignant disease</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 30 mg per mL in 10 mL vial</td>
<td><strong>Relapsing-remitting multiple sclerosis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ofloxacin</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 400 mg</td>
<td><strong>Multi-drug resistant Mycobacterium tuberculosis</strong></td>
</tr>
<tr>
<td><strong>Ear, nose and throat medicines [c]</strong></td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to ciprofloxacin for</td>
<td></td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Anti-infective agents</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.3%</td>
<td><strong>Infectious diseases of external ear</strong>; <strong>Other specified conjunctivitis</strong>; <strong>Infectious keratitis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Omadacycline</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg lyophilized powder for injection</td>
<td><strong>Methicillin resistant Staphylococcus aureus</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ombitasvir + paritaprevir + ritonavir</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for hepatitis C &gt; Non-pangenotypic direct-acting antiviral combinations</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 12.5 mg + 75 mg + 50 mg tablet</td>
<td><strong>Chronic hepatitis C</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Omeprazole</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiulcer medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid</td>
<td><strong>Gastro-oesophageal reflux disease</strong>; <strong>Peptic ulcer, site unspecified</strong>; <strong>Gastrointestinal bleeding</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg; 20 mg; 40 mg</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 40 mg in vial</td>
<td></td>
</tr>
</tbody>
</table>
### Ondansetron

<table>
<thead>
<tr>
<th>Medicines for other common symptoms in palliative care</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parenteral &gt; General injections &gt; IV:</strong> 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)</td>
</tr>
<tr>
<td><strong>Oral &gt; Liquid:</strong> 4 mg per 5 mL (ondansetron base)</td>
</tr>
<tr>
<td><strong>Oral &gt; Solid:</strong> 4 mg (ondansetron base); 8 mg (ondansetron base)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palliative care</td>
</tr>
<tr>
<td>Nausea or vomiting</td>
</tr>
</tbody>
</table>
### Oral rehydration salts

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral rehydration</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Powder for dilution in 200 mL, 500 mL, 1 L:</td>
<td></td>
</tr>
<tr>
<td>- glucose 75 mEq</td>
<td></td>
</tr>
<tr>
<td>- sodium 75 mEq or mmol/L</td>
<td></td>
</tr>
<tr>
<td>- chloride 65 mEq or mmol/L</td>
<td></td>
</tr>
<tr>
<td>- potassium 20 mEq or mmol/L</td>
<td></td>
</tr>
<tr>
<td>- citrate 10 mmol/L</td>
<td></td>
</tr>
<tr>
<td>- osmolarity 245 mOsm/L</td>
<td></td>
</tr>
<tr>
<td>- glucose 13.5 g/L</td>
<td></td>
</tr>
<tr>
<td>- sodium chloride 2.6 g/L</td>
<td></td>
</tr>
<tr>
<td>- potassium chloride 1.5 g/L</td>
<td></td>
</tr>
<tr>
<td>- trisodium citrate dihydrate 2.9 g/L</td>
<td></td>
</tr>
</tbody>
</table>

Solutions correcting water, electrolyte and acid-base disturbances > Oral

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for dilution in 200 mL, 500 mL, 1 L:</td>
<td>Other specified disorders of fluid, electrolyte or acid-base balance</td>
</tr>
<tr>
<td>- glucose 75 mEq</td>
<td></td>
</tr>
<tr>
<td>- sodium 75 mEq or mmol/L</td>
<td></td>
</tr>
<tr>
<td>- chloride 65 mEq or mmol/L</td>
<td></td>
</tr>
<tr>
<td>- potassium 20 mEq or mmol/L</td>
<td></td>
</tr>
<tr>
<td>- citrate 10 mmol/L</td>
<td></td>
</tr>
<tr>
<td>- osmolarity 245 mOsm/L</td>
<td></td>
</tr>
<tr>
<td>- glucose 13.5 g/L</td>
<td></td>
</tr>
<tr>
<td>- sodium chloride 2.6 g/L</td>
<td></td>
</tr>
<tr>
<td>- potassium chloride 1.5 g/L</td>
<td></td>
</tr>
<tr>
<td>- trisodium citrate dihydrate 2.9 g/L</td>
<td></td>
</tr>
</tbody>
</table>

### Oral rehydration salts - zinc sulfate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines used in diarrhoea</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Oral &gt; Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)</td>
<td></td>
</tr>
</tbody>
</table>

### Oseltamivir

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other antivirals</td>
<td>Influenza due to identified seasonal influenza virus</td>
</tr>
<tr>
<td>Oral &gt; Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)</td>
<td></td>
</tr>
</tbody>
</table>
### Osimertinib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
</tbody>
</table>

| Oral | Solid: 40 mg (as mesylate); 80 mg (as mesylate) |

### Oxaliplatin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td></td>
</tr>
</tbody>
</table>

| Parenteral | General injections | IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial |

| Malignant neoplasm metastasis in large intestine | Malignant neoplasms of colon |

### Oxamniquine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antischistosomals and other antitrematode medicines</td>
<td>Schistosomiasis due to Schistosoma mansoni</td>
</tr>
</tbody>
</table>

| Oral | Liquid: 250 mg per 5 mL |

| Oral | Solid: 250 mg capsule |

### Oxazolidinones

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reserve group antibiotics</td>
<td>Other specified bacterial diseases</td>
</tr>
</tbody>
</table>

### Oxycodone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid analgesics</td>
<td>Therapeutic equivalent to morphine for pain</td>
</tr>
</tbody>
</table>

### Oxygen

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>General anaesthetics and oxygen</td>
<td>Anaesthetics and therapeutic gases</td>
</tr>
</tbody>
</table>

| Inhalational medicines | Respiratory failure as acute or chronic |

| Respiratory | Inhalation: (medical gas) |

| Medical gases | Respiratory | Inhalation: |
**Oxytetracycline**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmological preparations &gt; Anti-infective agents</td>
<td>Therapeutic equivalent to tetracycline for</td>
</tr>
<tr>
<td></td>
<td>Other specified conjunctivitis</td>
</tr>
<tr>
<td></td>
<td>Infectious keratitis</td>
</tr>
<tr>
<td></td>
<td>Trachoma</td>
</tr>
<tr>
<td></td>
<td>Infectious blepharitis</td>
</tr>
</tbody>
</table>

**Oxytocin**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uterotonics</td>
<td>Postpartum haemorrhage</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 10 IU per mL</td>
<td></td>
</tr>
</tbody>
</table>

**P-aminosalicylic acid**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antituberculosis medicines</td>
<td>Multi-drug resistant Mycobacterium tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 4 g granules in sachet</td>
<td></td>
</tr>
</tbody>
</table>

**Paclitaxel**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td>Other specified malignant neoplasms of the ovary</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 6 mg per mL</td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of nasopharynx</td>
</tr>
<tr>
<td></td>
<td>Kaposi sarcoma of unspecified primary site</td>
</tr>
<tr>
<td></td>
<td>Other specified malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Other specified carcinomas of ovary</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of cervix uteri</td>
</tr>
</tbody>
</table>
### Palbociclib

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted therapies</strong></td>
<td>Other specified malignant neoplasms of breast</td>
</tr>
<tr>
<td>Oral &amp; Solid: 75 mg; 100 mg; 125 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Paliperidone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for psychotic disorders</strong></td>
<td>Schizophrenia or other primary psychotic disorders</td>
</tr>
<tr>
<td>Parenteral &amp; General injections &amp; IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)</td>
<td></td>
</tr>
</tbody>
</table>

### Palonosetron

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for other common symptoms in palliative care</strong></td>
<td>Therapeutic equivalent to ondansetron for Palliative care</td>
</tr>
<tr>
<td><strong>Antiemetic medicines</strong></td>
<td>Therapeutic equivalent to ondansetron for Nausea or vomiting</td>
</tr>
</tbody>
</table>

### Pancreatic enzymes

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pancreatic enzymes</strong></td>
<td>Enzyme intestinal</td>
</tr>
<tr>
<td>Oral &amp; Solid: Age-appropriate formulations and doses including lipase, protease and amylase.</td>
<td></td>
</tr>
</tbody>
</table>

### Paracetamol (acetaminophen)

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimigraine medicines &gt; For treatment of acute attack</strong></td>
<td>Migraine</td>
</tr>
<tr>
<td>Oral &amp; Liquid: 125 mg per 5 mL; 120 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &amp; Solid: 300 to 500 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)</strong></td>
<td>Pain</td>
</tr>
<tr>
<td>Oral &amp; Liquid: 125 mg per 5 mL; 120 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &amp; Solid: 100 to 500 mg</td>
<td></td>
</tr>
<tr>
<td>Local &amp; Rectal &amp; Suppository: 100 mg</td>
<td></td>
</tr>
</tbody>
</table>
### Paromomycin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antileishmaniasis medicines</strong></td>
<td>Visceral leishmaniasis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 750 mg paromomycin base (as sulfate)</td>
<td></td>
</tr>
<tr>
<td><strong>Antiamoebic and antiгиardiasis medicines</strong></td>
<td>Amoebiasis</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 125 mg per 5 mL as sulfate</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg as sulfate</td>
<td></td>
</tr>
</tbody>
</table>

### Pegasparagase

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 3750 units per 5 mL in vial</td>
<td></td>
</tr>
</tbody>
</table>

### Pegylated interferon alfa (2a)

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for hepatitis C &gt; Other antivirals for hepatitis C</strong></td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 180 µg in vial; 180 µg in prefilled syringe</td>
<td></td>
</tr>
</tbody>
</table>

### Pegylated interferon alfa (2b)

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for hepatitis C &gt; Other antivirals for hepatitis C</strong></td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe</td>
<td></td>
</tr>
</tbody>
</table>

### Pembrolizumab

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunomodulators</strong></td>
<td>Therapeutic equivalent to nivolumab for</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg powder for injection</td>
<td>Melanoma of skin</td>
</tr>
<tr>
<td></td>
<td>Other specified malignant neoplasms of bronchus or lung</td>
</tr>
</tbody>
</table>
## Penicillamine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Specific</td>
<td>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg</td>
<td></td>
</tr>
<tr>
<td>Disease-modifying anti-rheumatic drugs (DMARDs)</td>
<td>Rheumatoid arthritis, serology unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg</td>
<td></td>
</tr>
</tbody>
</table>

## Pentamidine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antileishmaniasis medicines</td>
<td>Visceral leishmaniasis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 200 mg (as isetionate); 300 mg (as</td>
<td></td>
</tr>
<tr>
<td>isetionate)</td>
<td></td>
</tr>
<tr>
<td>Antipneumocystosis and antitoxoplasmosis medicines</td>
<td>Pneumocystosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg tablet; 300 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Medicines for the treatment of 1st stage African trypanosomiasis</td>
<td>African trypanosomiasis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 200 mg (as isetionate) powder for</td>
<td></td>
</tr>
<tr>
<td>injection</td>
<td></td>
</tr>
</tbody>
</table>

## Permethrin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatological medicines &gt; Scabicides and pediculicides</td>
<td>Scabies</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 5%</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Lotion: 1%</td>
<td></td>
</tr>
<tr>
<td>Pediculosis corporis</td>
<td></td>
</tr>
<tr>
<td>Pediculosis capitis</td>
<td></td>
</tr>
</tbody>
</table>

## Pertussis vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for all immunization programmes</td>
<td>Need for immunization against pertussis alone</td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological</td>
<td></td>
</tr>
<tr>
<td>substances.</td>
<td></td>
</tr>
</tbody>
</table>

## Pertuzumab

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted therapies</td>
<td>Carcinoma of breast, specialised type</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 240 mg per 14 mL in vial</td>
<td></td>
</tr>
<tr>
<td>concentrated solution</td>
<td></td>
</tr>
</tbody>
</table>
### Phenobarbital

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 15 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 15 to 100 mg</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 200 mg per mL in ampoule (phenobarbital sodium)</td>
<td></td>
</tr>
</tbody>
</table>

### Phenoxymerphylpenicillin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg (as potassium salt) tablet</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)</td>
<td></td>
</tr>
</tbody>
</table>

### Phenytoin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 25 to 30 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 50 mg per mL in 5 vial (sodium salt)</td>
<td></td>
</tr>
</tbody>
</table>

### Phytomenadione

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines affecting coagulation</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 10 mg per mL in ampoule; 1 mg per mL in ampoule</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>

**Phenobarbital**

**Phenoxymerphylpenicillin**

**Phenytoin**

**Phytomenadione**
### Pilocarpine

**Section**

*Ophthalmological preparations > Miotics and antiglaucoma medicines*

**Indications**

- Primary open-angle glaucoma
- Acute angle closure with pupillary block
- Ocular hypertension

**Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)**

---

### Piperacillin + tazobactam

**Section**

**Watch group antibiotics**

*Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection*

**Indications**

- Peritoneal abscess (severe)
- Neutropenia (high-risk)
- Peritonitis (severe)
- Other specified pneumonia (Hospital-acquired pneumonia)

**Access group antibiotics**

*Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection*

**First choice**

- Necrotising fasciitis

**First choice**

- co-prescribed with clindamycin

---

### Platelets

**Section**

*Blood and blood components*

**Indications**

- Blood transfusion without reported diagnosis

**Parenteral > General injections > IV:**

---

### Plazomicin

**Section**

**Reserve group antibiotics**

*Parenteral > General injections > IV: 500 mg per 10 mL (Injection)*

**Indications**

- Carbapenem resistant Acinetobacter baumannii
- Carbapenem-resistant Pseudomonas aeruginosa
- Carbapenem resistant Enterobacterales
## Pneumococcal vaccine

### Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

- Need for immunization against single bacterial diseases

## Podophyllotoxin

### Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Therapeutic equivalent to podophyllum resin for
  - Plantar warts
  - Anogenital warts

## Podophyllum resin

### Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Plantar warts
- Anogenital warts

### Local > Topical > Solution: 10 to 25%

## Poliomyelitis vaccine

### Recommendations for all immunization programmes

All vaccines should comply with the WHO requirements for biological substances.

### Indications

- Need for immunization against poliomyelitis

## Polygeline

### Plasma substitutes

- Parenteral > General injections > IV: 3.5% injectable solution
- Parenteral > General injections > IV: 3.5% in solution

- Therapeutic equivalent to dextran 70 for
  - Hypovolaemia
  - Hypovolaemia
### Polymyxin B (injection)

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 500000 IU in vial powder</td>
<td></td>
</tr>
<tr>
<td>for injection</td>
<td></td>
</tr>
<tr>
<td><strong>Carbapenem-resistant Pseudomonas aeruginosa</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Carbapenem resistant Acinetobacter baumannii</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Carbapenem resistant Enterobacterales</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Polymyxins

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Other specified bacterial diseases</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Potassium chloride

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Solutions correcting water, electrolyte and acid-base disturbances</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)</td>
<td></td>
</tr>
<tr>
<td><strong>Hypokalaemia</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Potassium ferric hexacyanoferrate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antidotes and other substances used in poisonings</strong></td>
<td></td>
</tr>
<tr>
<td>Specific</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: Powder for oral administration</td>
<td></td>
</tr>
<tr>
<td><strong>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Potassium iodide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungal medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: Saturated solution</td>
<td></td>
</tr>
<tr>
<td><strong>Sporotrichosis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Thyroid hormones and antithyroid medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 60 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Thyrotoxicosis</strong></td>
<td></td>
</tr>
</tbody>
</table>
### Potassium permanganate

**Indications**

<table>
<thead>
<tr>
<th>Section</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatological medicines &gt; Anti-infective medicines</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: aqueous solution: 1:10 000</td>
<td></td>
</tr>
<tr>
<td>Other specified pyogenic bacterial infection of skin and subcutaneous tissue</td>
<td></td>
</tr>
<tr>
<td>Tropical phagedaenic ulcer</td>
<td></td>
</tr>
<tr>
<td>Pemphigus</td>
<td></td>
</tr>
<tr>
<td>Impetigo</td>
<td></td>
</tr>
</tbody>
</table>

### Povidone iodine

**Indications**

<table>
<thead>
<tr>
<th>Section</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiseptics</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: 10% (equivalent to 1% available iodine)</td>
<td></td>
</tr>
<tr>
<td>Povidone iodine</td>
<td></td>
</tr>
</tbody>
</table>

### Pralidoxime

**Indications**

<table>
<thead>
<tr>
<th>Section</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Specific</td>
<td></td>
</tr>
<tr>
<td>Exposure to or harmful effects of undetermined intent of pesticides</td>
<td></td>
</tr>
</tbody>
</table>

### Pramipexole

**Indications**

<table>
<thead>
<tr>
<th>Section</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiseizure medicines</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release</td>
<td></td>
</tr>
<tr>
<td>Parkinson disease</td>
<td></td>
</tr>
</tbody>
</table>

### Pravastatin

**Indications**

<table>
<thead>
<tr>
<th>Section</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid-lowering agents</td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia</td>
<td></td>
</tr>
<tr>
<td>Therapeutic equivalent to simvastatin for Coronary atherosclerosis</td>
<td></td>
</tr>
</tbody>
</table>
## Praziquantel

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intestinal anthelminths</strong>&lt;br&gt;Oral &gt; Solid: 600 mg tablet</td>
<td>Diphyllobothriasis&lt;br&gt;Taeniasis due to Taenia saginata&lt;br&gt;Taeniasis due to Taenia solium&lt;br&gt;Hymenolepiasis</td>
</tr>
<tr>
<td><strong>Antischistosomals and other antitrematode medicines</strong>&lt;br&gt;Oral &gt; Solid: 600 mg tablet</td>
<td>Paragonimiasis&lt;br&gt;Clonorchiasis&lt;br&gt;Opisthorchiasis&lt;br&gt;Schistosomiasis</td>
</tr>
<tr>
<td><strong>Cysticidal medicines</strong>&lt;br&gt;Oral &gt; Solid: 600 mg tablet; 500 mg tablet</td>
<td>Cysticercosis of central nervous system</td>
</tr>
</tbody>
</table>

## Precipitated sulfur

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatological medicines &gt; Scabicides and pediculicides</strong>&lt;br&gt;Local &gt; Topical &gt; Ointment:</td>
<td>Therapeutic equivalent to benzyl benzoate for&lt;br&gt;Pthiriasis&lt;br&gt;Pediculosis corporis&lt;br&gt;Pediculosis capitis&lt;br&gt;Scabies</td>
</tr>
</tbody>
</table>
### Prednisolone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormones and antihormones</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 5 mg per mL</td>
<td>Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg; 25 mg</td>
<td>Plasma cell myeloma</td>
</tr>
<tr>
<td></td>
<td>Follicular lymphoma</td>
</tr>
<tr>
<td></td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td></td>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
</tr>
<tr>
<td></td>
<td>Hodgkin lymphoma</td>
</tr>
<tr>
<td></td>
<td>Diffuse large B-cell lymphomas</td>
</tr>
<tr>
<td></td>
<td>Burkitt lymphoma including Burkitt leukaemia</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of prostate</td>
</tr>
<tr>
<td><strong>Anti-inflammatory medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Retention enema:</td>
<td>Therapeutic equivalent to hydrocortisone for</td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Retention enema: 20 mg per 100 mL</td>
<td>Crohn disease site</td>
</tr>
<tr>
<td>(as sodium phosphate)</td>
<td>Crohn disease site</td>
</tr>
<tr>
<td></td>
<td>Ulcerative colitis</td>
</tr>
<tr>
<td></td>
<td>Allergic or hypersensitivity conditions of unspecified type</td>
</tr>
<tr>
<td><strong>Antiallergics and medicines used in anaphylaxis</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 5 mg per mL</td>
<td>Scleritis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg; 25 mg</td>
<td>Anterior uveitis</td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Anti-inflammatory agents</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.5% (sodium phosphate)</td>
<td></td>
</tr>
</tbody>
</table>
### Prednisone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormones and antihormones</strong></td>
<td>Therapeutic equivalent to prednisolone for</td>
</tr>
<tr>
<td></td>
<td>Plasma cell myeloma</td>
</tr>
<tr>
<td></td>
<td>Follicular lymphoma</td>
</tr>
<tr>
<td></td>
<td>Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td></td>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
</tr>
<tr>
<td></td>
<td>Hodgkin lymphoma</td>
</tr>
<tr>
<td></td>
<td>Diffuse large B-cell lymphomas</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of prostate</td>
</tr>
<tr>
<td><strong>Antiallergics and medicines used in anaphylaxis</strong></td>
<td>Therapeutic equivalent to prednisolone for</td>
</tr>
<tr>
<td></td>
<td>Allergic or hypersensitivity conditions of unspecified type</td>
</tr>
</tbody>
</table>

### Primaquine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimalarial medicines &gt; For curative treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)</td>
<td>Malaria due to Plasmodium ovale</td>
</tr>
<tr>
<td></td>
<td>Malaria due to Plasmodium vivax</td>
</tr>
</tbody>
</table>

### Probenecid

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines used to treat gout</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg</td>
<td>Gout</td>
</tr>
</tbody>
</table>

### Procanamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiarrhythmic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg per mL in 10 mL ampoule (hydrochloride)</td>
<td>Cardiac arrhythmia</td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>
### Procaine benzylpenicillin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Access group antibiotics | **First choice** *Congenital syphilis [children]*  
Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection | **Second choice** *Syphilis* |

### Procarbazine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Cytotoxic medicines | Unspecified malignant neoplasms of ill-defined or unspecified sites  
Oral > Solid: 50 mg (as hydrochloride)  
Hodgkin lymphoma |

### Progesterone vaginal ring

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Intravaginal contraceptives | Contact with health services for contraceptive management  
Local > Vaginal > vaginal ring: 2.074 g micronized progesterone |

### Proguanil

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Antimalarial medicines > For chemoprevention | *Malaria due to Plasmodium falciparum*  
Oral > Solid: 100 mg tablet (hydrochloride) |

### Promethazine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Antiemetic medicines | **Nausea or vomiting**  
Oral > Liquid: 5 mg per 5 mL (hydrochloride)  
Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)  
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule |

### Propanol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiseptics</td>
<td>Therapeutic equivalent to <em>ethanol</em> for Denatured alcohol</td>
</tr>
</tbody>
</table>
### Propofol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>General anaesthetics and oxygen &gt; Injectable medicines</td>
<td>Anaesthetics and therapeutic gases</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL; 20 mg per mL</td>
<td></td>
</tr>
</tbody>
</table>

### Propranolol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihypertensive medicines</td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>Antianginal medicines</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 mg in 1 mL ampoule (hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>Antiarrhythmic medicines</td>
<td>Cardiac arrhythmia</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 mg in 1 mL ampoule (hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>Antimigraine medicines &gt; For prophylaxis</td>
<td>Migraine</td>
</tr>
<tr>
<td>Oral &gt; Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>

### Propylthiouracil

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid hormones and antithyroid medicines</td>
<td>Thyrotoxicosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Prostaglandin E1

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines administered to the neonate [c]</td>
<td>Other specified congenital anomaly of great arteries including arterial duct</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 0.5 mg per mL in alcohol</td>
<td></td>
</tr>
</tbody>
</table>

### Prostaglandin E2

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines administered to the neonate [c]</td>
<td>Therapeutic equivalent to prostaglandin E1 for Other specified congenital anomaly of great arteries including arterial duct</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 mg per mL</td>
<td></td>
</tr>
</tbody>
</table>
### Medicines affecting coagulation

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protamine sulfate</strong></td>
<td><strong>Haemorrhagic disorder due to other specified circulating anticoagulants</strong></td>
</tr>
</tbody>
</table>

**Indications**

**Parenteral > General injections > IV:** 10 mg per mL in 5 mL ampoule

### Intestinal anthelminthics

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pyrantel</strong></td>
<td><strong>Ascariasis</strong></td>
</tr>
</tbody>
</table>

**Indications**

**Oral > Liquid:** 50 mg per mL (as embonate or pamoate)

**Oral > Solid:** 250 mg chewable tablet (as embonate or pamoate)

### Antituberculosis medicines

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pyrazinamide</strong></td>
<td><strong>Tuberculosis</strong></td>
</tr>
</tbody>
</table>

**Indications**

**Oral > Liquid:** 30 mg per mL

**Oral > Solid:** 400 mg; 150 mg tablet (dispersible); 500 mg

### Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pyridostigmine</strong></td>
<td><strong>Myasthenia gravis</strong></td>
</tr>
</tbody>
</table>

**Indications**

**Parenteral > General injections > IV:** 1 mg in 1 mL ampoule (pyridostigmine bromide)

**Oral > Solid:** 60 mg (pyridostigmine bromide)

### Vitamins and minerals

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pyridoxine</strong></td>
<td><strong>Vitamin B6 deficiency</strong></td>
</tr>
</tbody>
</table>

**Indications**

**Oral > Solid:** 25 mg (hydrochloride)

### Antipneumocystosis and antitoxoplasmosis medicines

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pyrimethamine</strong></td>
<td><strong>Toxoplasmosis</strong></td>
</tr>
</tbody>
</table>

**Indications**

**Oral > Solid:** 25 mg
<table>
<thead>
<tr>
<th><strong>Quinidine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiarrhythmic medicines</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg (sulfate)</td>
<td>Cardiac arrhythmia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Quinine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimalarial medicines</strong> &gt; For curative treatment</td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)</td>
<td>Malaria due to Plasmodium falciparum</td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 mg (quinine sulfate or quinine bisulfate)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rabies vaccine</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendations for some high-risk populations</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against rabies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Raltegravir</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiretrovirals</strong> &gt; Integrase inhibitors</td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 100 mg granules for oral suspension</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg tablet; 25 mg tablet (chewable)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ranibizumab</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ophthalmological preparations</strong> &gt; Anti-vascular endothelial growth factor (VEGF) preparations</td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Retinal venous occlusions</td>
<td>Diabetic macular oedema</td>
</tr>
<tr>
<td>Degenerative high myopia</td>
<td>Age related macular degeneration</td>
</tr>
</tbody>
</table>
### Antiulcer medicines

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Liquid: 75 mg per 5 mL (as hydrochloride)</td>
<td>Peptic ulcer, site unspecified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg (as hydrochloride)</td>
<td>Gastro-oesophageal reflux disease</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)</td>
<td></td>
</tr>
</tbody>
</table>

### Rasburicase

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supportive medicines</td>
<td>Tumour lysis syndrome</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution</td>
<td></td>
</tr>
</tbody>
</table>

### Ready to use therapeutic food

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solutions correcting water, electrolyte and acid–base disturbances</td>
<td>Acute malnutrition in infants, children or adolescents</td>
</tr>
<tr>
<td>Lipid-based paste for oral consumption.</td>
<td></td>
</tr>
</tbody>
</table>

### Realgar-indigo naturalis formulation

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxic medicines</td>
<td>Acute myeloid leukaemia with recurrent genetic abnormalities</td>
</tr>
<tr>
<td>Oral &gt; Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)</td>
<td></td>
</tr>
</tbody>
</table>

### Red blood cells

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and blood components</td>
<td>Blood transfusion without reported diagnosis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV:</td>
<td></td>
</tr>
</tbody>
</table>
### Retinol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamins and minerals</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection</td>
<td>Vitamin A deficiency</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule</td>
<td></td>
</tr>
</tbody>
</table>

### Ribavirin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Other antivirals</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution</td>
<td>Viral haemorrhagic fever, not elsewhere classified</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 400 mg; 600 mg</td>
<td></td>
</tr>
<tr>
<td>Medicines for hepatitis C &gt; Other antivirals for hepatitis C</td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 400 mg; 600 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Riboflavin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamins and minerals</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg</td>
<td>Vitamin B2 deficiency</td>
</tr>
</tbody>
</table>

### Rifabutin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg per mL</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg; 300 mg</td>
<td><strong>Other specified tuberculosis</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 600 mg in vial powder for injection</td>
<td></td>
</tr>
<tr>
<td><strong>Antileprosy medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg; 300 mg</td>
<td>Leprosy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rifampicin</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg per mL</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg; 300 mg</td>
<td><strong>Other specified tuberculosis</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 600 mg in vial powder for injection</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rifapentine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antituberculosis medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 20 mg per mL</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg tablet; 300 mg tablet</td>
<td>Latent tuberculosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risperidone</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Medicines for psychotic disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg</td>
<td>Schizophrenia or other primary psychotic disorders</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ritonavir</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Antiretrovirals &gt; Protease inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)</td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rituximab</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Targeted therapies</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial</td>
<td>Follicular lymphoma</td>
</tr>
<tr>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
<td></td>
</tr>
<tr>
<td>Diffuse large B-cell lymphomas</td>
<td></td>
</tr>
</tbody>
</table>
## Rivaroxaban

<table>
<thead>
<tr>
<th>Medicines affecting coagulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Therapeutic equivalent to dabigatran for</td>
</tr>
<tr>
<td></td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td></td>
<td>Therapeutic equivalent to dabigatran for</td>
</tr>
<tr>
<td></td>
<td>Other specified atrial fibrillation</td>
</tr>
</tbody>
</table>

## Ropinirole

<table>
<thead>
<tr>
<th>Antiseizure medicines</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release</td>
<td>Parkinson disease</td>
</tr>
</tbody>
</table>

## Rotavirus vaccine

<table>
<thead>
<tr>
<th>Recommendations for all immunization programmes</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against certain single viral diseases</td>
</tr>
</tbody>
</table>

## Rubella vaccine

<table>
<thead>
<tr>
<th>Recommendations for all immunization programmes</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against rubella alone</td>
</tr>
</tbody>
</table>

## Salbutamol

<table>
<thead>
<tr>
<th>Antiasthmatic and medicines for chronic obstructive pulmonary disease</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 µg per mL in 5 mL ampoule (as sulfate)</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>Respiratory &gt; Inhalation &gt; aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler</td>
<td>Asthma</td>
</tr>
<tr>
<td>Respiratory &gt; Inhalation &gt; solution: 5 mg per mL (as sulfate) for use in nebulizers</td>
<td></td>
</tr>
<tr>
<td><strong>Salicylic acid</strong></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Section</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</td>
<td>Seborrhoeic dermatitis</td>
</tr>
<tr>
<td></td>
<td>Psoriasis of unspecified type</td>
</tr>
<tr>
<td></td>
<td>Ichthyoses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Saquinavir</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Antiretrovirals &gt; Protease inhibitors</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg; 500 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Selenium sulfide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Antifungal medicines</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Senna</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 7.5 mg per 5 mL oral liquid</td>
</tr>
<tr>
<td>Laxatives</td>
</tr>
<tr>
<td>Oral &gt; Solid: 7.5 mg (sennosides) (or traditional dosage forms)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Silver diamine fluoride</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Dental medicines and preparations</td>
</tr>
<tr>
<td>Local &gt; Dental &gt; Solution: 38% w/v</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Silver nitrate</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section</strong></td>
</tr>
<tr>
<td>Ophthalmological preparations &gt; Anti-infective agents</td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 1%</td>
</tr>
<tr>
<td>Section</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td><strong>Silver sulfadiazine</strong></td>
</tr>
<tr>
<td>Dermatological medicines &gt; Anti-infective medicines</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 1%</td>
</tr>
<tr>
<td><strong>Simeprevir</strong></td>
</tr>
<tr>
<td>Medicines for hepatitis C &gt; Non-pangenotypic direct-acting antiviral combinations</td>
</tr>
<tr>
<td>Oral &gt; Solid: 150 mg</td>
</tr>
<tr>
<td><strong>Simvastatin</strong></td>
</tr>
<tr>
<td>Lipid-lowering agents</td>
</tr>
<tr>
<td>Oral &gt; Solid: 5 mg; 10 mg; 20 mg; 40 mg</td>
</tr>
<tr>
<td>Medicines for endocrine disorders</td>
</tr>
<tr>
<td>Oral &gt; Solid: 20 mg</td>
</tr>
<tr>
<td><strong>Smallpox vaccine</strong></td>
</tr>
<tr>
<td>Recommendations for all immunization programmes</td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
</tr>
<tr>
<td><strong>Snake antivenom</strong></td>
</tr>
<tr>
<td>Immunologicals &gt; Sera, immunoglobulins and monoclonal antibodies</td>
</tr>
<tr>
<td><strong>Sodium calcium edetate</strong></td>
</tr>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Specific</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 200 mg per mL in 5 mL ampoule</td>
</tr>
</tbody>
</table>
### Sodium chloride

**Solutions correcting water, electrolyte and acid-base disturbances > Parenteral**

Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)

**Indications**

Other specified disorders of fluid, electrolyte or acid-base balance

### Sodium hydrogen carbonate

**Solutions correcting water, electrolyte and acid-base disturbances > Parenteral**

Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)

**Indications**

Acidosis

### Sodium nitrite

**Antidotes and other substances used in poisonings > Specific**

Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

**Indications**

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

### Sodium nitroprusside

**Antihypertensive medicines**

Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

**Indications**

Hypertensive crisis

### Sodium stibogluconate

**Antileishmaniasis medicines**

Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

**Indications**

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis
### Sodium thiosulfate

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatological medicines &gt; Antifungal medicines</td>
<td>Pityriasis versicolor</td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Solution: 15%</td>
<td></td>
</tr>
<tr>
<td>Antidotes and other substances used in poisonings &gt; Specific</td>
<td>Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 250 mg per mL in 50 mL ampoule</td>
<td></td>
</tr>
</tbody>
</table>

### Sofosbuvir

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for hepatitis C &gt; Pangenotypic direct-acting antiviral combinations</td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg; 200 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Sofosbuvir + velpatasvir

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for hepatitis C &gt; Pangenotypic direct-acting antiviral combinations</td>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Oral &gt; Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>

### Spectinomycin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access group antibiotics</td>
<td>Second choice</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 2 g in vial (as hydrochloride) powder for injection</td>
<td>Gonococcal infection</td>
</tr>
<tr>
<td>Other indications</td>
<td>Bacterial infection of unspecified site</td>
</tr>
</tbody>
</table>

### Spironolactone

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines used in heart failure</td>
<td>Heart failure</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td></td>
</tr>
<tr>
<td>Diuretics</td>
<td>Oedema</td>
</tr>
<tr>
<td>Oral &gt; Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL</td>
<td>Ascites</td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td></td>
</tr>
</tbody>
</table>
### Stavudine

**Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors**

**Oral**
- Liquid: 5 mg per 5 mL powder for oral solution
- Solid: 15 mg; 20 mg; 30 mg

**Indications**
- Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

### Streptokinase

**Thrombolytic medicines**

**Parenteral > General injections > IV**
- 1.5 million IU in vial powder for injection

**Indications**
- Acute myocardial infarction

### Streptomycin (injection)

**Antituberculosis medicines**

**Parenteral > General injections > IV**
- 1 g powder for injection (as sulfate) as vial

**Indications**
- Multi-drug resistant Mycobacterium tuberculosis

### Succimer

**Antidotes and other substances used in poisonings > Specific**

**Oral > Solid**
- 100 mg

**Indications**
- Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

### Sulfacetamide

**Ophthalmological preparations > Anti-infective agents**

**Local > Ophthalmological > Ointment**
- 10% (sodium salt)

**Indications**
- Other specified conjunctivitis

### Sulfadiazine

**Antipneumocystosis and antitoxoplasmosis medicines**

**Oral > Solid**
- 500 mg

**Indications**
- Toxoplasmosis
### Sulfadoxine + pyrimethamine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimalarial medicines &gt; For curative treatment</td>
<td>Malaria due to <em>Plasmodium falciparum</em>&lt;br&gt;Malaria due to <em>Plasmodium vivax</em></td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg + 25 mg tablet</td>
<td></td>
</tr>
<tr>
<td>Antimalarial medicines &gt; For chemoprevention</td>
<td>Malaria due to <em>Plasmodium falciparum</em>&lt;br&gt;Malaria</td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg + 25 mg tablet&lt;br&gt;Oral &gt; Solid: 250 mg + 12.5 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>

### Sulfamethoxazole + trimethoprim

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access group antibiotics</td>
<td><strong>First choice</strong>&lt;br&gt;Infectious cystitis&lt;br&gt;&lt;br&gt;<strong>Second choice</strong>&lt;br&gt;Infectious gastroenteritis or colitis without specification of infectious agent</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule&lt;br&gt;Oral &gt; Liquid: 200 mg + 40 mg per 5 mL oral liquid&lt;br&gt;Oral &gt; Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet</td>
<td><strong>Other indications</strong>&lt;br&gt;Bacterial infection of unspecified site&lt;br&gt;Pneumocystosis</td>
</tr>
<tr>
<td>Antipneumocystosis and antitoxoplasmosis medicines</td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule&lt;br&gt;Oral &gt; Liquid: 200 mg + 40 mg per 5 mL oral liquid&lt;br&gt;Oral &gt; Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet</td>
<td></td>
</tr>
</tbody>
</table>

### Sulfasalazine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-modifying anti-rheumatic drugs (DMARDs)</td>
<td>Rheumatoid arthritis, serology unspecified&lt;br&gt;Crohn disease site&lt;br&gt;Ulcerative colitis</td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg</td>
<td></td>
</tr>
<tr>
<td>Anti-inflammatory medicines</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 500 mg</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Suppository: 500 mg</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Rectal &gt; Retention enema:</td>
<td></td>
</tr>
</tbody>
</table>

### Sumatriptan

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimigraine medicines &gt; For treatment of acute attack</td>
<td>Migraine</td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Suramin sodium</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Antifilarials</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 g in vial</td>
<td>Filariais</td>
</tr>
<tr>
<td><strong>Medicines for the treatment of 1st stage African trypanosomiasis</strong></td>
<td>African trypanosomiasis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 1 g in vial</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Surfactant</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines administered to the neonate [c]</td>
<td>Respiratory distress syndrome of newborn</td>
</tr>
<tr>
<td>Respiratory &gt; Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Suxamethonium</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Muscle relaxants (peripherally-acting) and cholinesterase inhibitors</strong></td>
<td>Muscle relaxants</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tacalcitol</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</strong></td>
<td>Therapeutic equivalent to calcipotriol for</td>
</tr>
<tr>
<td>Psoriasis of unspecified type</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tacrolimus</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunomodulators for non-malignant disease</strong></td>
<td>Failure or rejection of transplanted organs or tissues</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 5 mg per mL in 1 mL vial</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Hormones and antihormones</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 10 mg (as citrate); 20 mg (as citrate)</td>
<td>Other specified malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td><strong>Telmisartan + amlodipine</strong></td>
<td></td>
</tr>
<tr>
<td>Antihypertensive medicines</td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Telmisartan + hydrochlorothiazide</strong></td>
<td></td>
</tr>
<tr>
<td>Antihypertensive medicines</td>
<td>Essential hypertension</td>
</tr>
<tr>
<td>Oral &gt; Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Tenofovir alafenamide</strong></td>
<td>Chronic hepatitis B</td>
</tr>
<tr>
<td>Medicines for hepatitis B &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 25 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Tenofovir disoproxil fumarate</strong></td>
<td>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</td>
</tr>
<tr>
<td>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)</td>
<td>Contact with or exposure to human immunodeficiency virus</td>
</tr>
<tr>
<td>Medicines for hepatitis B &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</td>
<td>Chronic hepatitis B</td>
</tr>
<tr>
<td>Oral &gt; Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)</td>
<td></td>
</tr>
<tr>
<td><strong>Terbinafine</strong></td>
<td>Fungal infection of the skin</td>
</tr>
<tr>
<td>Dermatological medicines &gt; Antifungal medicines</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Cream: 1% terbinafine hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Local &gt; Topical &gt; Ointment: 1% terbinafine hydrochloride</td>
<td></td>
</tr>
</tbody>
</table>
### Terbutaline

**Section**

**Antiasthmatic and medicines for chronic obstructive pulmonary disease**

**Indications**

Therapeutic equivalent to salbutamol for

- **Chronic obstructive pulmonary disease**
- **Asthma**

### Terizidone

**Section**

**Antituberculosis medicines**

**Indications**

Therapeutic equivalent to cycloserine for

- **Multi-drug resistant Mycobacterium tuberculosis**

### Testosterone

**Section**

**Androgens**

**Parenteral > General injections > IM**: 200 mg per mL in 1 mL ampoule (enantate)

**Indications**

- **Testicular dysfunction or testosterone-related disorders**

### Tetanus antitoxin

**Section**

**Immunologicals > Sera, immunoglobulins and monoclonal antibodies**

**Parenteral > General injections > IM**: 50000 IU in vial

**Indications**

- **Tetanus**

### Tetanus vaccine

**Section**

**Recommendations for all immunization programmes**

All vaccines should comply with the WHO requirements for biological substances.

**Indications**

- **Need for immunization against tetanus alone**

### Tetracaine

**Section**

**Ophthalmological preparations > Local anaesthetics**

**Local > Ophthalmological > Solution (eye drops)**: 0.5% (hydrochloride)

**Indications**

- **Local anaesthetics**
**Tetracycline**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg (hydrochloride)</td>
<td>Bacterial infection of unspecified site</td>
</tr>
<tr>
<td><strong>Ophthalmological preparations &gt; Anti-infective agents</strong></td>
<td></td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Ointment: 1% (tetracycline hydrochloride)</td>
<td>Neonatal conjunctivitis or dacryocystitis</td>
</tr>
<tr>
<td></td>
<td>Other specified conjunctivitis</td>
</tr>
<tr>
<td></td>
<td>Infectious keratitis</td>
</tr>
<tr>
<td></td>
<td>Trachoma</td>
</tr>
<tr>
<td></td>
<td>Infectious blepharitis</td>
</tr>
</tbody>
</table>

**Thalidomide**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunomodulators</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg</td>
<td>Plasma cell myeloma</td>
</tr>
</tbody>
</table>

**Thiamine**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamins and minerals</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 50 mg (hydrochloride)</td>
<td>Vitamin B1 deficiency</td>
</tr>
</tbody>
</table>

**Thiopental**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General anaesthetics and oxygen &gt; Injectable medicines</strong></td>
<td>Therapeutic equivalent to propofol for anaesthetics and therapeutic gases</td>
</tr>
</tbody>
</table>

**Tick-borne encephalitis vaccine**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendations for certain regions</strong></td>
<td></td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against arthropod-borne viral encephalitis</td>
</tr>
</tbody>
</table>

**Tigecycline**

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reserve group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 50 mg in vial powder for injection</td>
<td>Other specified bacterial diseases</td>
</tr>
</tbody>
</table>
### Timolol

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ophthalmological preparations &gt; Miotics and antiglaucoma medicines</strong></td>
<td><strong>Ocular hypertension</strong>&lt;br&gt;<strong>Primary open-angle glaucoma</strong></td>
</tr>
<tr>
<td><strong>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Tioguanine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td><strong>Lymphoid leukaemia, not elsewhere classified</strong></td>
</tr>
<tr>
<td><strong>Oral &gt; Solid: 40 mg</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Tiotropium bromide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiasthmatic and medicines for chronic obstructive pulmonary disease</strong></td>
<td><strong>Chronic obstructive pulmonary disease</strong></td>
</tr>
<tr>
<td><strong>Respiratory &gt; Inhalation &gt; dry powder: 18 µg capsule</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory &gt; Inhalation &gt; solution: 1.25 µg per actuation; 2.5 µg per actuation</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Tislelizumab

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunomodulators</strong></td>
<td><strong>Malignant neoplasms of urinary tract</strong>&lt;br&gt;<strong>Hodgkin lymphoma</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; IV: 100 mg per 10 mL</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Tobramycin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ophthalmological preparations &gt; Anti-infective agents</strong></td>
<td>Therapeutic equivalent to gentamicin for&lt;br&gt;&lt;br&gt;<strong>Other specified conjunctivitis</strong>&lt;br&gt;&lt;br&gt;Therapeutic equivalent to gentamicin for&lt;br&gt;&lt;br&gt;<strong>Infectious blepharitis</strong></td>
</tr>
</tbody>
</table>

### Tocilizumab

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for juvenile joint diseases</strong></td>
<td><strong>Juvenile systemic arthritis</strong></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Parenteral &gt; General injections &gt; SC: 162 mg per 0.9 mL in pre-filled syringe</strong></td>
<td></td>
</tr>
</tbody>
</table>
### Tolbutamide

**Oral hypoglycaemic agents**

| Oral > Solid: 500 mg |

**Indications**

- Type 2 diabetes mellitus

### Tramadol

**Opioid analgesics**

| Oral > Liquid: 100 mg per mL (hydrochloride) |
| Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release |
| Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride) |

**Indications**

- Chronic cancer pain

### Trametinib

**Targeted therapies**

| Oral > Solid: 0.5 mg; 2 mg |

**Indications**

- Other specified melanoma of skin

### Tranexamic acid

**Medicines affecting coagulation**

| Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule |

**Indications**

- Haemorrhage, not elsewhere classified

| Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule |

**Indications**

- Postpartum haemorrhage

### Trastuzumab

**Targeted therapies**

| Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection |

**Indications**

- Carcinoma of breast, specialised type
<table>
<thead>
<tr>
<th><strong>Trastuzumab emtansine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted therapies</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection</td>
</tr>
<tr>
<td><strong>Carcinoma of breast, specialised type</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Triamcinolone hexacetonide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for juvenile joint diseases</strong></td>
</tr>
<tr>
<td>Parenteral &gt; Locoregional injections &gt; Intra-articular: 20 mg per mL in 2 mL vial; 20 mg per mL in 10 mL vial</td>
</tr>
<tr>
<td><strong>Juvenile idiopathic arthritis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Triclabendazole</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antischistosomes and other antitrematode medicines</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg tablet</td>
</tr>
<tr>
<td><strong>Fascioliasis</strong></td>
</tr>
<tr>
<td><strong>Paragonimiasis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Trihexyphenidyl</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)</td>
</tr>
<tr>
<td>Therapeutic equivalent to biperiden for Parkinson disease</td>
</tr>
<tr>
<td><strong>Parkinson disease</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Trimethoprim</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access group antibiotics</strong></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per mL</td>
</tr>
<tr>
<td>Oral &gt; Solid: 100 mg; 200 mg</td>
</tr>
<tr>
<td><strong>First choice</strong></td>
</tr>
<tr>
<td><strong>Infectious cystitis</strong></td>
</tr>
</tbody>
</table>
### Triptorelin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormones and antihormones</td>
<td>Therapeutic equivalent to leuprolin for:</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of breast</td>
</tr>
<tr>
<td></td>
<td>Malignant neoplasms of prostate</td>
</tr>
</tbody>
</table>

### Tropicamide

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic agents &gt; Ophthalmic medicines</td>
<td>Cycloplegic drug</td>
</tr>
<tr>
<td>Local &gt; Ophthalmological &gt; Solution (eye drops): 0.5%</td>
<td></td>
</tr>
</tbody>
</table>

### Tropisetron

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicines for other common symptoms in palliative care</td>
<td>Therapeutic equivalent to ondansetron for:</td>
</tr>
<tr>
<td></td>
<td>Palliative care</td>
</tr>
<tr>
<td>Antiemetic medicines</td>
<td>Therapeutic equivalent to ondansetron for:</td>
</tr>
<tr>
<td></td>
<td>Nausea or vomiting</td>
</tr>
</tbody>
</table>

### Tuberculin, purified protein derivative

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunologicals &gt; Diagnostic agents</td>
<td>Mycobacterial diseases</td>
</tr>
<tr>
<td>Parenteral &gt; Locoregional injections &gt; Intradermal:</td>
<td></td>
</tr>
</tbody>
</table>

### Tubocurarine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle relaxants (peripherally-acting) and cholinesterase inhibitors</td>
<td>Muscle relaxants</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)</td>
<td></td>
</tr>
</tbody>
</table>

### Typhoid vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for some high-risk populations</td>
<td>Need for immunization against typhoid-paratyphoid alone</td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td></td>
</tr>
</tbody>
</table>
### Ulipristal

**Oral hormonal contraceptives**

**Oral > Solid: 30 mg tablet (ulipristal acetate)**

*Contact with health services for postcoital contraception*

### Umeclidinium

**Antiasthmatic and medicines for chronic obstructive pulmonary disease**

*Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease*

### Urea

**Dermatological medicines > Medicines affecting skin differentiation and proliferation**

**Local > Topical > Cream: 10%; 5%**

**Local > Topical > Ointment: 10%; 5%**

### Valaciclovir

**Antiherpes medicines**

*Therapeutic equivalent to aciclovir for Zoster*

*Therapeutic equivalent to aciclovir for Varicella*

*Therapeutic equivalent to aciclovir for Herpes simplex infections*

### Valganciclovir

**Other antivirals**

**Oral > Liquid: 50 mg per mL powder for oral solution**

**Oral > Solid: 450 mg Tablet**

*Cyto megaloviral retinitis*
### Valproic acid (sodium valproate)

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiseizure medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 200 mg per 5 mL</td>
<td>Epilepsy or seizures</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)</td>
<td>Status epilepticus</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule</td>
<td></td>
</tr>
<tr>
<td><strong>Medicines for bipolar disorders</strong></td>
<td>Bipolar or related disorders</td>
</tr>
<tr>
<td>Oral &gt; Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)</td>
<td></td>
</tr>
</tbody>
</table>

### Vancomycin

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Watch group antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 250 mg in vial (as hydrochloride) powder for injection</td>
<td>First choice</td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 125 mg (as hydrochloride); 250 mg (as hydrochloride)</td>
<td>Other indications</td>
</tr>
<tr>
<td>co-prescribed with ceftazidime</td>
<td></td>
</tr>
<tr>
<td>co-prescribed with ceftriaxone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Second choice</strong></td>
<td></td>
</tr>
<tr>
<td>Intestinal infections due to Clostridioides difficile</td>
<td></td>
</tr>
<tr>
<td>Neutropenia (high-risk)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other indications</strong></td>
<td></td>
</tr>
<tr>
<td>Methicillin resistant Staphylococcus aureus</td>
<td></td>
</tr>
</tbody>
</table>

### Varenicline

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medicines for disorders due to psychoactive substance use</strong></td>
<td>Nicotine dependence</td>
</tr>
<tr>
<td>Oral &gt; Solid: 0.5 mg; 1 mg</td>
<td></td>
</tr>
</tbody>
</table>

### Varicella vaccine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendations for immunization programmes with certain characteristics</strong></td>
<td>Need for immunization against certain single viral diseases</td>
</tr>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td></td>
</tr>
</tbody>
</table>
### Vecuronium

**Muscle relaxants (peripherally-acting) and cholinesterase inhibitors**

Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

### Vemurafenib

**Targeted therapies**

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

### Verapamil

**Antiarrhythmic medicines**

Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

**Antianginal medicines**

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

### Vinblastine

**Cytotoxic medicines**

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
### Vincristine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Unspecified malignant neoplasms of ill-defined or unspecified sites</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Other specified gliomas of brain</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Malignant trophoblastic neoplasms of placenta</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Follicular lymphoma</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Malignant neoplasms of kidney, except renal pelvis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Ewing sarcoma of bone and articular cartilage of unspecified sites</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Kaposi sarcoma of unspecified primary site</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Rhabdomyosarcoma primary site</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Hodgkin lymphoma</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Diffuse large B-cell lymphomas</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Retinoblastoma</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Burkitt lymphoma including Burkitt leukaemia</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Lymphoid leukaemia, not elsewhere classified</td>
</tr>
<tr>
<td>Oral &gt; Solid</td>
<td></td>
</tr>
</tbody>
</table>

### Vinorelbine

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Other specified malignant neoplasms of bronchus or lung</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Other specified malignant neoplasms of breast</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Rhabdomyosarcoma primary site</td>
</tr>
<tr>
<td>Oral &gt; Solid</td>
<td></td>
</tr>
</tbody>
</table>

### Voriconazole

<table>
<thead>
<tr>
<th>Section</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungal medicines</strong></td>
<td></td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Chronic pulmonary aspergillosis</td>
</tr>
<tr>
<td>Parenteral &gt; General injections</td>
<td>- Invasive aspergillosis</td>
</tr>
<tr>
<td>Oral &gt; Solid</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid</td>
<td></td>
</tr>
</tbody>
</table>
### Warfarin

<table>
<thead>
<tr>
<th>Medicines affecting coagulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)</td>
<td>Other specified diseases of arteries or arterioles</td>
</tr>
<tr>
<td></td>
<td>Cerebral ischaemic stroke due to embolic occlusion</td>
</tr>
<tr>
<td></td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td></td>
<td>Atrial fibrillation</td>
</tr>
</tbody>
</table>

### Water for injection

<table>
<thead>
<tr>
<th>Solutions correcting water, electrolyte and acid-base disturbances &gt; Miscellaneous</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule</td>
<td>Unspecified appropriateness of dosing or administration without injury or harm</td>
</tr>
</tbody>
</table>

### Whole blood

<table>
<thead>
<tr>
<th>Blood and blood components</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral &gt; General injections &gt; IV:</td>
<td>Blood transfusion without reported diagnosis</td>
</tr>
</tbody>
</table>

### Xylometazoline

<table>
<thead>
<tr>
<th>Ear, nose and throat medicines [c]</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local &gt; Nasal &gt; Spray: 0.05% w/v equivalent to 0.5 mg per mL</td>
<td>Nasal congestion</td>
</tr>
</tbody>
</table>

### Yellow fever vaccine

<table>
<thead>
<tr>
<th>Recommendations for certain regions</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines should comply with the WHO requirements for biological substances.</td>
<td>Need for immunization against certain single viral diseases</td>
</tr>
</tbody>
</table>

### Zanubrutinib

<table>
<thead>
<tr>
<th>Targeted therapies</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral &gt; Solid: 80 mg</td>
<td>Mantle cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>Chronic lymphocytic leukaemia or small lymphocytic lymphoma</td>
</tr>
<tr>
<td>Section</td>
<td>Indications</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Antiretrovirals &gt; Nucleoside/Nucleotide reverse transcriptase inhibitors</td>
<td><strong>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 10 mg per mL in 20 mL vial solution for IV infusion injection</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Liquid: 50 mg per 5 mL</td>
<td></td>
</tr>
<tr>
<td>Oral &gt; Solid: 250 mg capsule; 300 mg tablet</td>
<td></td>
</tr>
<tr>
<td><strong>Zidovudine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Zinc sulfate</strong></td>
<td></td>
</tr>
<tr>
<td>Medicines for diarrhoea</td>
<td><strong>Diarrhoea</strong></td>
</tr>
<tr>
<td>Oral &gt; Solid: 20 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Zoledronic acid</strong></td>
<td></td>
</tr>
<tr>
<td>Supportive medicines</td>
<td><strong>Malignant neoplasm metastasis in bone or bone marrow</strong></td>
</tr>
<tr>
<td>Parenteral &gt; General injections &gt; IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle</td>
<td></td>
</tr>
</tbody>
</table>